<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T08:38:17Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7955363" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7955363</identifier>
        <datestamp>2021-03-17</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7955363</article-id>
              <article-id pub-id-type="pmcid">PMC7955363</article-id>
              <article-id pub-id-type="pmc-uid">7955363</article-id>
              <article-id pub-id-type="pmid">33289422</article-id>
              <article-id pub-id-type="pmid">33289422</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.120.017870</article-id>
              <article-id pub-id-type="publisher-id">JAH35745</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Valvular Heart Disease</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Comparison of Early Surgical or Transcatheter Aortic Valve Replacement Versus Conservative Management in Low‐Flow, Low‐Gradient Aortic Stenosis Using Inverse Probability of Treatment Weighting: Results From the TOPAS Prospective Observational Cohort Study</article-title>
                <alt-title alt-title-type="right-running-head">Treating Low‐Flow, Low‐Gradient Aortic Stenosis</alt-title>
                <alt-title alt-title-type="left-running-head">Annabi et al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah35745-cr-0001" contrib-type="author">
                  <name>
                    <surname>Annabi</surname>
                    <given-names>Mohamed‐Salah</given-names>
                  </name>
                  <degrees>MD, MSc</degrees>
                  <xref ref-type="aff" rid="jah35745-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah35745-cr-0002" contrib-type="author">
                  <name>
                    <surname>Côté</surname>
                    <given-names>Nancy</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah35745-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah35745-cr-0003" contrib-type="author">
                  <name>
                    <surname>Dahou</surname>
                    <given-names>Abdellaziz</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="jah35745-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah35745-cr-0004" contrib-type="author">
                  <name>
                    <surname>Bartko</surname>
                    <given-names>Philipp E.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="jah35745-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah35745-cr-0005" contrib-type="author">
                  <name>
                    <surname>Bergler‐Klein</surname>
                    <given-names>Jutta</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah35745-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah35745-cr-0006" contrib-type="author">
                  <name>
                    <surname>Burwash</surname>
                    <given-names>Ian G.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah35745-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah35745-cr-0007" contrib-type="author">
                  <name>
                    <surname>Orwat</surname>
                    <given-names>Stefan</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2836-6333</contrib-id>
                  <xref ref-type="aff" rid="jah35745-aff-0004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jah35745-cr-0008" contrib-type="author">
                  <name>
                    <surname>Baumgartner</surname>
                    <given-names>Helmut</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah35745-aff-0004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jah35745-cr-0009" contrib-type="author">
                  <name>
                    <surname>Mascherbauer</surname>
                    <given-names>Julia</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah35745-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah35745-cr-0010" contrib-type="author">
                  <name>
                    <surname>Mundigler</surname>
                    <given-names>Gerald</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah35745-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah35745-cr-0011" contrib-type="author">
                  <name>
                    <surname>Fukui</surname>
                    <given-names>Miho</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="jah35745-aff-0006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="jah35745-cr-0012" contrib-type="author">
                  <name>
                    <surname>Cavalcante</surname>
                    <given-names>Joao</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah35745-aff-0005">
                    <sup>5</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah35745-aff-0006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="jah35745-cr-0013" contrib-type="author">
                  <name>
                    <surname>Ribeiro</surname>
                    <given-names>Henrique B.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="jah35745-aff-0007">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="jah35745-cr-0014" contrib-type="author">
                  <name>
                    <surname>Rodès‐Cabau</surname>
                    <given-names>Josep</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8237-7095</contrib-id>
                  <xref ref-type="aff" rid="jah35745-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah35745-cr-0015" contrib-type="author">
                  <name>
                    <surname>Clavel</surname>
                    <given-names>Marie‐Annick</given-names>
                  </name>
                  <degrees>DVM, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8924-740X</contrib-id>
                  <xref ref-type="aff" rid="jah35745-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah35745-cr-0016" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Pibarot</surname>
                    <given-names>Philippe</given-names>
                  </name>
                  <degrees>DVM, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3607-279X</contrib-id>
                  <xref ref-type="aff" rid="jah35745-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>philippe.pibarot@fmed.ulaval.ca</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="jah35745-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <institution>Institut Universitaire de Cardiologie et de Pneumologie de Québec‐Université Laval</institution>
                <city>Québec</city>
                <country country="CA">Canada</country>
              </aff>
              <aff id="jah35745-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Division of Cardiology</named-content>
                <named-content content-type="organisation-division">Department of Internal Medicine II</named-content>
                <institution>Medical University of Vienna</institution>
                <institution>Vienna General Hospital</institution>
                <city>Vienna</city>
                <country country="AT">Austria</country>
              </aff>
              <aff id="jah35745-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <institution>University of Ottawa Heart Institute</institution>
                <city>Ottawa</city>
                <named-content content-type="country-part">Ontario</named-content>
                <country country="CA">Canada</country>
              </aff>
              <aff id="jah35745-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Department of Cardiology III–Adult Congenital and Valvular Heart Disease</named-content>
                <institution>University Hospital Muenster</institution>
                <city>Muenster</city>
                <country country="DE">Germany</country>
              </aff>
              <aff id="jah35745-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Division of Cardiology</named-content>
                <institution>University of Pittsburgh</institution>
                <named-content content-type="country-part">PA</named-content>
              </aff>
              <aff id="jah35745-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Cardiology</named-content>
                <institution>Minneapolis Heart Institute</institution>
                <city>Minneapolis</city>
                <named-content content-type="country-part">MN</named-content>
              </aff>
              <aff id="jah35745-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <institution>Heart Institute of São Paulo (InCor)</institution>
                <institution>University of São Paulo</institution>
                <country country="BR">Brazil</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>
Correspondence to: Philippe Pibarot, DVM, PhD, 2725 Chemin Ste‐Foy A‐2047, Québec City (QC) G1V4G5, Canada. E‐mail: <email>philippe.pibarot@fmed.ulaval.ca</email><break/></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>08</day>
                <month>12</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>15</day>
                <month>12</month>
                <year>2020</year>
              </pub-date>
              <volume>9</volume>
              <issue>24</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.v9.24</issue-id>
              <elocation-id>e017870</elocation-id>
              <history>
                <date date-type="received">
                  <day>26</day>
                  <month>6</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>22</day>
                  <month>10</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright">Copyright &#x000a9; 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell<copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license license-type="creativeCommonsBy-nc-nd">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JAH3-9-e017870.pdf"/>
              <abstract id="jah35745-abs-0001">
                <sec id="jah35745-sec-0001">
                  <title>Background</title>
                  <p>No randomized comparison of early (ie, ≤3 months) aortic valve replacement (AVR) versus conservative management or of transcatheter AVR (TAVR) versus surgical AVR has been conducted in patients with low‐flow, low‐gradient (LFLG) aortic stenosis (AS).</p>
                </sec>
                <sec id="jah35745-sec-0002">
                  <title>Methods and Results</title>
                  <p>A total of 481 consecutive patients (75±10 years; 71% men) with LFLG AS (aortic valve area ≤0.6 cm<sup>2</sup>/m<sup>2</sup> and mean gradient &lt;40 mm Hg), 72% with classic LFLG and 28% with paradoxical LFLG, were prospectively recruited in the multicenter TOPAS (True or Pseudo Severe Aortic Stenosis) study. True‐severe AS or pseudo‐severe AS was adjudicated by flow‐independent criteria. During follow‐up (median [IQR] 36 [11–60] months), 220 patients died. Using inverse probability of treatment weighting to address the bias of nonrandom treatment assignment, early AVR (n=272) was associated with a major overall survival benefit (hazard ratio [HR], 0.34 [95% CI, 0.24–0.50]; <italic>P</italic>&lt;0.001). This benefit was observed in patients with true‐severe AS but also with pseudo‐severe AS (HR, 0.38 [95% CI, 0.18–0.81]; <italic>P</italic>=0.01), and in classic (HR, 0.33 [95% CI, 0.22–0.49]; <italic>P</italic>&lt;0.001) and paradoxical LFLG AS (HR, 0.42 [95% CI, 0.20–0.92]; <italic>P</italic>=0.03). Compared with conservative management in the conventional multivariate model, trans femoral TAVR was associated with the best survival (HR, 0.23 [95% CI, 0.12–0.43]; <italic>P</italic>&lt;0.001), followed by surgical AVR (HR, 0.36 [95% CI, 0.23–0.56]; <italic>P</italic>&lt;0.001) and alternative‐access TAVR (HR, 0.51 [95% CI, 0.31–0.82]; <italic>P</italic>=0.007). In the inverse probability of treatment weighting model, trans femoral TAVR appeared to be superior to surgical AVR (HR [95% CI] 0.28 [0.11–0.72]; <italic>P</italic>=0.008) with regard to survival.</p>
                </sec>
                <sec id="jah35745-sec-0003">
                  <title>Conclusions</title>
                  <p>In this large prospective observational study of LFLG AS, early AVR appeared to confer a major survival benefit in both classic and paradoxical LFLG AS. This benefit seems to extend to the subgroup with pseudo‐severe AS. Our findings suggest that TAVR using femoral access might be the best strategy in these patients.</p>
                </sec>
                <sec id="jah35745-sec-0004">
                  <title>Registration</title>
                  <p>URL: <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</ext-link>; Unique identifier: NCT01835028.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd id="jah35745-kwd-0001">aortic stenosis</kwd>
                <kwd id="jah35745-kwd-0002">low flow</kwd>
                <kwd id="jah35745-kwd-0003">low gradient</kwd>
                <kwd id="jah35745-kwd-0004">surgical aortic valve replacement</kwd>
                <kwd id="jah35745-kwd-0005">survival</kwd>
                <kwd id="jah35745-kwd-0006">transcatheter aortic valve replacement</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Valvular Heart Disease</kwd>
                <kwd>Aortic Valve Replacement/Transcather Aortic Valve Implantation</kwd>
                <kwd>Mortality/Survival</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>Canadian Institutes of Health Research </institution>
                      <institution-id institution-id-type="open-funder-registry">10.13039/501100000024</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>MOP‐57445</award-id>
                  <award-id>MOP‐126072</award-id>
                  <award-id>FDN‐143225</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="3"/>
                <table-count count="1"/>
                <page-count count="12"/>
                <word-count count="8202"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>15 December 2020</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.7 mode:remove_FC converted:19.02.2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jah35745-cit-1001">(<source xml:lang="en">J Am Heart Assoc</source>. <year>2020</year>;<volume>9</volume>:<elocation-id>e017870</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/JAHA.120.017870</pub-id>.)<pub-id pub-id-type="pmid">33289422</pub-id></mixed-citation>
              </p>
              <fn-group id="jah35745-ntgp-0001">
                <fn id="jah35745-note-0001">
                  <p>Supplementary Material for this article is available at <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/JAHA.120.017870">https://www.ahajournals.org/doi/suppl/10.1161/JAHA.120.017870</ext-link>
</p>
                </fn>
                <fn id="jah35745-note-0002">
                  <p>For Sources of Funding and Disclosures, see page 11.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="jah35745-body-0001">
            <def-list list-content="abbreviations" id="jah35745-lp-0001">
              <title>Nonstandard Abbreviations and Acronyms</title>
              <def-item>
                <term>AS</term>
                <def>
                  <p>aortic stenosis</p>
                </def>
              </def-item>
              <def-item>
                <term>AVA</term>
                <def>
                  <p>aortic valve area</p>
                </def>
              </def-item>
              <def-item>
                <term>AVA<sub>Proj</sub></term>
                <def>
                  <p>projected aortic valve area at normal flow rate</p>
                </def>
              </def-item>
              <def-item>
                <term>AVR</term>
                <def>
                  <p>aortic valve replacement</p>
                </def>
              </def-item>
              <def-item>
                <term>ConsRx</term>
                <def>
                  <p>conservative management</p>
                </def>
              </def-item>
              <def-item>
                <term>IPTW</term>
                <def>
                  <p>inverse probability of treatment weighting</p>
                </def>
              </def-item>
              <def-item>
                <term>LFLG</term>
                <def>
                  <p>low flow, low gradient</p>
                </def>
              </def-item>
              <def-item>
                <term>PSAS</term>
                <def>
                  <p>pseudo‐severe aortic stenosis</p>
                </def>
              </def-item>
              <def-item>
                <term>SAVR</term>
                <def>
                  <p>surgical aortic valve replacement</p>
                </def>
              </def-item>
              <def-item>
                <term>SMD</term>
                <def>
                  <p>standardized mean difference</p>
                </def>
              </def-item>
              <def-item>
                <term>TAVR</term>
                <def>
                  <p>transcatheter aortic valve replacement</p>
                </def>
              </def-item>
              <def-item>
                <term>TOPAS</term>
                <def>
                  <p>True or Pseudo Severe Aortic Stenosis</p>
                </def>
              </def-item>
              <def-item>
                <term>TSAS</term>
                <def>
                  <p>true‐severe aortic stenosis</p>
                </def>
              </def-item>
              <def-item>
                <term>wHR</term>
                <def>
                  <p>weighted hazard ratio</p>
                </def>
              </def-item>
            </def-list>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah35745-blkfxd-0001" orientation="portrait">
                <sec id="jah35745-sec-0006">
                  <title>Clinical Perspective</title>
                  <sec id="jah35745-sec-0007">
                    <title>What Is New?</title>
                    <p>
                      <list list-type="bullet" id="jah35745-list-0001">
                        <list-item>
                          <p>According to this large prospective observational cohort study, early aortic valve replacement is superior to clinical surveillance in both classic and paradoxical low‐flow, low‐gradient aortic stenosis, whether with true‐severe or pseudo‐severe (ie, moderate) aortic stenosis. Transcatheter aortic valve replacement appears to be the best therapeutic option, especially using femoral access.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                  <sec id="jah35745-sec-0008">
                    <title>What Are the Clinical Implications?</title>
                    <p>
                      <list list-type="bullet" id="jah35745-list-0002">
                        <list-item>
                          <p>Early aortic valve replacement, especially with transcatheter transfemoral approach should be considered in symptomatic patients with low‐flow, low‐gradient AS.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                </sec>
              </boxed-text>
            </p>
            <sec sec-type="opening-section" id="jah35745-sec-0009">
              <p>Close to 40% of patients with aortic stenosis (AS) with aortic valve area (AVA) ≤1.0 cm<sup>2</sup> have a low mean gradient (&lt;40 mm Hg), thereby raising uncertainty as to the actual severity of the disease and whether aortic valve replacement (AVR) is warranted.<xref rid="jah35745-bib-0001" ref-type="ref"><sup>1</sup></xref>, <xref rid="jah35745-bib-0002" ref-type="ref"><sup>2</sup></xref> In a large proportion of these patients, the small AVA–low‐gradient pattern is related to a low‐flow state, which is defined as a stroke volume index ≤35 mL/m<sup>2</sup>. This low‐flow, low‐gradient (LFLG) AS entity may occur with either a depressed left ventricular ejection fraction (LVEF; &lt;50%) (ie, classic LFLG AS) or with a preserved LVEF (ie, paradoxical LFLG AS), a phenotype close to heart failure with preserved LVEF.<xref rid="jah35745-bib-0003" ref-type="ref"><sup>3</sup></xref> According to guidelines, AVR is recommended (class I or IIa) in patients with LFLG AS if the presence of true‐severe AS (TSAS) is confirmed using dobutamine stress echocardiography or aortic valve calcium scoring by computed tomography.<xref rid="jah35745-bib-0004" ref-type="ref"><sup>4</sup></xref>, <xref rid="jah35745-bib-0005" ref-type="ref"><sup>5</sup></xref>, <xref rid="jah35745-bib-0006" ref-type="ref"><sup>6</sup></xref> However, because of low sensitivity (35%), only a minority of patients with classic LFLG AS would qualify for AVR according to dobutamine stress criteria for TSAS proposed in the guidelines.<xref rid="jah35745-bib-0007" ref-type="ref"><sup>7</sup></xref> Moreover, studies reported that 50% to 78% of patients with LFLG AS have TSAS based on aortic valve calcification scoring.<xref rid="jah35745-bib-0008" ref-type="ref"><sup>8</sup></xref>, <xref rid="jah35745-bib-0009" ref-type="ref"><sup>9</sup></xref> On the other hand, patients with pseudo‐severe AS (PSAS) (ie, moderate AS and left ventricular systolic heart failure) have a poor outcome under conservative management (ConsRx), and data suggest they may benefit from surgical AVR (SAVR).<xref rid="jah35745-bib-0010" ref-type="ref"><sup>10</sup></xref>, <xref rid="jah35745-bib-0011" ref-type="ref"><sup>11</sup></xref> Thus, most patients with LFLG AS might benefit from AVR. There is no randomized trial comparing the different treatment strategies in patients with LFLG AS. In this report, inverse probability of treatment weighting (IPTW) was used to compare AVR versus ConsRx and SAVR versus transcatheter AVR (TAVR) in a large prospective observational study of patients with LFLG AS.</p>
            </sec>
            <sec sec-type="methods" id="jah35745-sec-0010">
              <title>Methods</title>
              <sec id="jah35745-sec-0011">
                <title>Population</title>
                <p>The data that support the findings of this study are available from the corresponding author on reasonable request. A total of 481 patients were prospectively recruited in the TOPAS (True or Pseudo Severe Aortic Stenosis) study from 5 centers. The design and methods of this prospective multicenter observational study have been previously described (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link>; NCT 01835028).<xref rid="jah35745-bib-0012" ref-type="ref"><sup>12</sup></xref>, <xref rid="jah35745-bib-0013" ref-type="ref"><sup>13</sup></xref>, <xref rid="jah35745-bib-0014" ref-type="ref"><sup>14</sup></xref> Briefly, patients were included in the TOPAS study if they had a mean gradient &lt;40 mm Hg and an indexed AVA ≤0.6 cm<sup>2</sup>/m<sup>2</sup> and were classified as classic LFLG AS if LVEF was &lt;50% and paradoxical LFLG AS if it was ≥50%. Patients with preserved LVEF and a stroke volume index &gt;35 mL/m<sup>2</sup> were excluded, whereas those with depressed LVEF were recruited regardless of stroke volume. Patients were also excluded if they had more than mild aortic regurgitation, more than moderate mitral regurgitation, or more than mild mitral stenosis (following multiparameter integrative approach, as recommended).<xref rid="jah35745-bib-0015" ref-type="ref"><sup>15</sup></xref>, <xref rid="jah35745-bib-0016" ref-type="ref"><sup>16</sup></xref>, <xref rid="jah35745-bib-0017" ref-type="ref"><sup>17</sup></xref> Other exclusion criteria were end‐stage chronic kidney disease, severe cognitive impairment (also excluded for inability to sign informed consent), acute coronary syndrome or acutely decompensated heart failure within 3 months before inclusion, and any severe illness with an expected survival of &lt;1 year. The institutional review board committee of the participating centers approved the study. All the subjects provided written informed consent. Study enrollment started in 2002, and the last patient was recruited in 2016. Collected baseline clinical data were age, sex, body surface area, Duke activity status index, hypertension, hyperlipidemia, diabetes mellitus, chronic kidney disease (as defined by an estimated glomerular filtration rate &lt;60 mL/s following Cockroft and Gault method), atrial fibrillation/flutter, history of myocardial infarction, history of coronary artery bypass grafting, coronary artery disease (ie, ≥50% coronary artery stenosis on coronary angiography), history of stroke or transient ischemic attack, peripheral artery disease, the European System for Cardiac Operative Risk Evaluation II score, congestive heart failure, New York Heart Association functional class, acute pulmonary edema, and chronic obstructive pulmonary disease. Resting and peak dobutamine stress AVA, mean gradient, and LVEF values were collected. NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) was measured at baseline (Roche Diagnostics). Starting from 2012, an amendment was performed to add aortic valve calcification scoring using multidetector computed tomography in the study protocol. Echocardiographic and tomographic analyses were performed in a CoreLab at the Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, QC, Canada. After SAVR, the explanted valves were collected. The treatment strategy (ie, early AVR [SAVR or TAVR] or ConsRx) was left to the discretion of the treating physician and heart team. If AVR was performed within 3 months following the inclusion date, the strategy was considered as early AVR, whereas if AVR was not performed during follow‐up or was performed &gt;3 months following inclusion, the strategy was considered as ConsRx. We recorded any combined revascularization (combined coronary artery bypass grafting or percutaneous revascularization within 30 days of the TAVR procedure) or other heart valve intervention. Patients were prospectively followed up with yearly scheduled visits or by telephone until study completion (ie, at 5 years of follow‐up).</p>
              </sec>
              <sec id="jah35745-sec-0012">
                <title>Adjudication of AS Severity</title>
                <p>The determination of true AS severity was based on at least one of the following flow‐independent parameters:
<list list-type="order" id="jah35745-list-0003"><list-item><p>Aortic valve calcification ratio (n=154). This ratio is calculated by dividing the aortic valve calcium score (using the Agatston method) by the currently recommended sex‐specific cut points for TSAS (ie, 1200 and 2000 arbitrary units in women and men, respectively).<xref rid="jah35745-bib-0008" ref-type="ref"><sup>8</sup></xref>, <xref rid="jah35745-bib-0018" ref-type="ref"><sup>18</sup></xref> A value of aortic valve calcification ratio ≥1.0 defined TSAS.</p></list-item><list-item><p>Projected AVA at normal flow rate (AVA<sub>Proj</sub>; n=206) with a value ≤1.0 cm<sup>2</sup> to define TSAS (see Data <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S1</xref> for detailed AVA<sub>Proj</sub> method).<xref rid="jah35745-bib-0007" ref-type="ref"><sup>7</sup></xref>, <xref rid="jah35745-bib-0019" ref-type="ref"><sup>19</sup></xref>
</p></list-item><list-item><p>Aortic valve weight ratio (n=106) calculated by dividing the actual valve weight by the previously reported sex‐specific cut points for TSAS (ie, 1.2 g for women and 2.0 g for men).<xref rid="jah35745-bib-0020" ref-type="ref"><sup>20</sup></xref> A value of aortic valve weight ratio ≥1.0 defined TSAS.</p></list-item><list-item><p>Confirmation of stenosis severity by a macroscopic evaluation of the valve performed by the surgeon at the time of SAVR (n=131), following a standardized and previously validated method.<xref rid="jah35745-bib-0012" ref-type="ref"><sup>12</sup></xref>, <xref rid="jah35745-bib-0013" ref-type="ref"><sup>13</sup></xref>
</p></list-item></list>
</p>
                <p>Patients were categorized as having TSAS if at least one of the criteria was fulfilled, regardless to the results of the others. Patients with no available flow‐independent parameters of AS severity were considered as having indeterminate AS severity.</p>
              </sec>
              <sec id="jah35745-sec-0013">
                <title>Statistical Analysis</title>
                <p>Continuous variables are expressed as mean±SD or median (25th–75th percentile) for normally and not normally distributed variables, respectively (as tested by Shapiro‐Wilk test) and were compared using Student <italic>t</italic> test (or <italic>U</italic> test of Wilcoxon‐Mann‐Whitney, as appropriate) and ANOVA (followed by Tukey post hoc test or Kruskall‐Wallis followed by Dunn test) for multiple comparison. Proportions are expressed as percentages and compared using χ<sup>2</sup> test or Fisher exact test, as appropriate. IPTW was used to address the bias related to nonrandom assignment of treatment.<xref rid="jah35745-bib-0021" ref-type="ref"><sup>21</sup></xref> This method allows increasing the weight of underrepresented observations to reduce the imbalances related to treatment allocation, thereby simulating the effect of randomization on baseline characteristics. Details on IPTW method are provided in Data <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S1</xref>. Briefly, a propensity score was built using multiple logistic regression (Table <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S1</xref>), taking early AVR versus ConsRx as a binary end point. To compare the different types of AVR, the propensity score using the same regression model was recalculated for TAVR versus ConsRx, SAVR versus ConsRx, and TAVR versus SAVR. Second, each patient was weighted by the inverse probability of treatment (eg, 1/propensity score for patients undergoing AVR and 1/[1−propensity score] for patients receiving ConsRx; see weight distribution in Figure <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S1</xref>). The balance between the treatment groups was assessed using weighted standardized mean difference (SMD; ie, percentage of the pooled SD). An SMD value ≤20% was considered acceptable. The association of treatment with 3‐year all‐cause death was analyzed using weighted Kaplan‐Meier curves and Cox proportional hazards regression with a robust variance estimator to calculate weighted hazard ratios (wHRs) (95% CIs). Proportional hazard's assumption was verified using Schoenfield residuals. Residual differences between treatment groups after IPTW were adjusted for by forcing the insufficiently balanced variables into the weighted model (providing adjusted wHR). To mimic the intention‐to‐treat analysis of a randomized trial, patients receiving ConsRx who “crossed over” to AVR were analyzed in the ConsRx group. We also analyzed delayed AVR as a time‐dependent variable. To study the benefit of AVR according to true AS severity and according to the type of LFLG AS (classic and paradoxical), we performed interaction‐term and subgroup analyses. Standard (ie, with no weighting) Kaplan‐Meier curves and univariable and multivariable Cox proportional hazards regression were used to analyze both SAVR and TAVR (femoral and alternative access) versus ConsRx (referent) and to verify the consistency with IPTW analyses. A 2‐sided <italic>P</italic>&lt;0.05 was considered for statistical significance. Statistical analyses were performed with SPSS version 25 (SPSS, Inc, Chicago, IL) and STATA version 15.1 (StataCorp 2017, College Station, TX).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="jah35745-sec-0014">
              <title>Results</title>
              <p>Baseline characteristics of the population are summarized in the <xref rid="jah35745-tbl-0001" ref-type="table">Table</xref>. The mean age was 75±10 years, and 71% of the study population were men. The average indexed AVA and mean gradient values were 0.43±0.12 cm<sup>2</sup>/m<sup>2</sup> and 26±9 mm Hg, respectively. The average LVEF was 38±17%, and 72% (n=344) had classic LFLG (LVEF &lt;50%) and 28% (n=137) had paradoxical LFLG AS (LVEF ≥50%). There was a high prevalence of comorbidities in these patients (<xref rid="jah35745-tbl-0001" ref-type="table">Table</xref>). The prevalence of stage III to IV New York Heart Association functional class (55%; n=259) and the low Duke activity status index (median, 19 [25th–75th percentile, 10–31]) reflected poor functional status. Among patients who underwent a flow‐independent assessment of AS severity (n=425), 69% (n=293) were confirmed with TSAS: 68% in the classic LFLG group and 72% in the paradoxical LFLG group (<italic>P</italic>=0.33). Among the 80 patients with both a priori (either AVA<sub>Proj</sub> or aortic valve calcification score) and a posteriori (either aortic valve weight or macroscopic assessment at the time of SAVR), 13 (16%) had PSAS with both evaluations. The results of each grading scheme are reported in the <xref rid="jah35745-tbl-0001" ref-type="table">Table</xref>. A total of 411 patients (97%) had at least one quantitative grading scheme (aortic valve calcification or weight ratios and AVA<sub>Proj</sub>). A comparison between patients with PSAS and TSAS is provided in Table <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S2</xref> and described in Data <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S1</xref>. The adjudication of AS severity revealed that the vast majority of patients with confirmed PSAS had a moderate stenosis, which was close to the severe AS cut points, therefore suggesting that AS severity was moderate or moderate to severe in this group with unlikely occurrence of mild AS. Finally, 274 patients (57%) underwent early AVR (ie, with a median delay from inclusion of 0 [25th–75th percentile, 0–1] months). Of these patients, 189 had classic LFLG and 85 had paradoxical LFLG AS (55% and 62%, respectively; <italic>P</italic>=0.16).</p>
              <sec id="jah35745-sec-0015">
                <title>Survival Benefit Associated With Early AVR</title>
                <p>A comparison of baseline characteristics between early AVR and ConsRx groups is described in Data <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S1</xref> and summarized in Table <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S3</xref>. All of the baseline differences were balanced after IPTW except residual borderline differences in LVEF (SMD=24%) and peripheral artery disease (SMD=25%). Of note, although 42% of ConsRx group versus 76% in the AVR group had a confirmed TSAS before IPTW, this variable was evenly distributed between treatment groups (60% versus 66%, respectively; SMD=12%) after IPTW.</p>
                <p>During a median follow‐up of 36 months (25th–75th percentile, 11–60 months), 220 patients died and 4 (&lt;1%) were lost to follow‐up (2 patients from the ConsRx group and 2 from the AVR group [1 from SAVR and 1 from TAVR subgroups]). Early AVR was associated with major survival benefit (wHR, 0.33 [95% CI, 0.23–0.48]; adjusted wHR, 0.34 [95% CI, 0.24–0.50]; both <italic>P</italic>&lt;0.0001; Figure <xref rid="jah35745-fig-0001" ref-type="fig">1A</xref>) compared with ConsRx. This result was consistent in the nonweighted population and was not altered by clustering effect of the participating centers (Figure <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S2</xref>; adjusted hazard ratio [HR], 0.42 [95% CI, 0.28–0.61]; <italic>P</italic>&lt;0.001 using mixed effect survival model). More important, 38 patients from the ConsRx group eventually crossed over to AVR after a median time of 12 (25th–75th percentile, 8–24) months from inclusion. When entering delayed (ie, performed &gt;3 months after inclusion) AVR as a time‐dependent covariate, there was a trend toward improved outcome (adjusted HR, 0.39 [95% CI, 0.14–1.08]; <italic>P</italic>=0.07), whereas early AVR remained strongly and independently associated with lower mortality (adjusted HR, 0.41 [95% CI, 0.30–0.56]; <italic>P</italic>&lt;0.001). Analyzing both overall AVR (early and delayed) as a time‐dependent covariate provided similar results (adjusted HR, 0.46 [95% CI, 0.34–0.63]; <italic>P</italic>&lt;0.001).</p>
                <fig fig-type="Figure" xml:lang="en" id="jah35745-fig-0001" orientation="portrait" position="float">
                  <label>Figure 1</label>
                  <caption>
                    <title>Survival benefit associated with aortic valve replacement (AVR) in low‐flow, low‐gradient aortic stenosis (LFLG AS) using inverse probability of treatment weighting (IPTW).</title>
                    <p>In <bold>A</bold>, early (ie, ≤3 months) AVR (red line) is compared with conservative management or clinical surveillance and delayed AVR (blue line). The forest plot in (<bold>B</bold>) shows the weighted hazard ratio (HR) associated with AVR in the different study subgroups. In (<bold>C</bold>), the survival curves are stratified according to the initial management strategy and the severity of AS, excluding patients with indeterminate AS severity. The survival curves are adjusted using IPTW. The weighted numbers at risk are simulated and thus not shown (see Figure <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S1</xref> for the weights' distributions). The adjusted weighted HRs are adjusted for residual differences after IPTW (Table <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S3</xref>). PSAS indicates pseudo‐severe AS; and TSAS, true‐severe AS.</p>
                  </caption>
                  <graphic id="nlm-graphic-1" xlink:href="JAH3-9-e017870-g001"/>
                </fig>
                <p>The forest plot in Figure <xref rid="jah35745-fig-0001" ref-type="fig">1B</xref> shows the association of early AVR with mortality across the study subgroups. Interestingly, the survival benefit associated with AVR was observed not only in the subgroup with TSAS (wHR, 0.30 [95% CI, 0.19–0.48]) but also in the patients with PSAS (wHR, 0.38 [95% CI, 0.18–0.81], <italic>P</italic>=0.01; adjusted wHR, 0.36 [95% CI, 0.17–0.78], <italic>P</italic>=0.009). Moreover, no significant interaction was found between TSAS/PSAS status and early AVR with respect to mortality (<italic>P</italic>=0.54). As shown in Figure <xref rid="jah35745-fig-0001" ref-type="fig">1C</xref>, the worst 3‐year survival rate was observed in the patients with TSAS with initial ConsRx (wHR, 1.54 [95% CI, 0.96–2.48]; <italic>P</italic>=0.07) compared with conservatively managed patients with PSAS, whereas patients with TSAS or PSAS undergoing early AVR had the best survival despite higher 30‐day mortality (4.9% and 8.0% for TSAS and PSAS, respectively, after AVR versus 6.7% and 0.8%, respectively, with ConsRx; <italic>P</italic>=0.05). These results were consistent in the nonweighted population (Figure <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S3</xref>). We also found no interaction between classic/paradoxical LFLG and AVR with mortality (<italic>P</italic>=0.50 for interaction) and, as shown in Figure <xref rid="jah35745-fig-0001" ref-type="fig">1B</xref> and Figure <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S4</xref>, the better survival associated with early AVR was consistent in classic (wHR, 0.33 [95% CI, 0.22–0.49]; <italic>P</italic>&lt;0.001) and paradoxical LFLG AS (wHR, 0.42 [95% CI, 0.20–0.92]; <italic>P</italic>=0.03).</p>
              </sec>
              <sec id="jah35745-sec-0016">
                <title>Survival Benefit Associated With Early TAVR Versus SAVR</title>
                <p>Baseline characteristics according to the treatment type (ie, SAVR [n=175], TAVR [n=97], and ConsRx [n=205]) are summarized in the <xref rid="jah35745-tbl-0001" ref-type="table">Table</xref>. Briefly, patients undergoing TAVR had the highest baseline risk profile: they were the oldest (80±7 versus 71±10 and 75±10 years old in the SAVR and ConsRx groups, respectively; <italic>P</italic>&lt;0.001 and all post hoc <italic>P</italic>&lt;0.05), with the worst functional status, as measured by the New York Heart Association class (71% New York Heart Association class III–IV versus 61% and 43% in SAVR and ConsRx groups, respectively; <italic>P</italic>&lt;0.001) or the Duke activity status index (median, 10 [25th–75th percentile, 7–16] versus 19 [25th–75th percentile, 13–29] and 24 [25th–75th percentile, 13–38] in SAVR and ConsRx groups, respectively; <italic>P</italic>&lt;0.001 and all post hoc <italic>P</italic>&lt;0.05), and the highest prevalence of cardiac and noncardiac comorbidities, resulting in the highest EuroSCORE II (9.6% [25th–75th percentile, 7.0%–15.2%] versus 3.1% [25th–75th percentile, 1.7%–6.1%] and 4.9% [25th–75th percentile, 2.4%–8.0%] in SAVR and ConsRx groups, respectively; <italic>P</italic>&lt;0.001 and all post hoc <italic>P</italic>&lt;0.05). TSAS was present in 50% of ConsRx group versus 86% and 74% of the SAVR and TAVR groups, respectively (<italic>P</italic>&lt;0.001).</p>
                <p>During follow‐up, patients with ConsRx had the worst survival (Figure <xref rid="jah35745-fig-0002" ref-type="fig">2A</xref>). TAVR (HR, 0.67 [95% CI, 0.46–0.98]; <italic>P</italic>=0.04) and SAVR (HR, 0.32 [95% CI, 0.22–0.48]; <italic>P</italic>&lt;0.001) were associated with a significantly better survival compared with ConsRx. In multivariable analysis performed in the nonweighted population and taking ConsRx as the referent group, both SAVR (adjusted HR, 0.36 [95% CI, 0.23–0.56]; <italic>P</italic>&lt;0.001) and TAVR (HR, 0.36 [95% CI, 0.23–0.55]; <italic>P</italic>&lt;0.001) were independently associated with a better survival. When subdividing the TAVR group into transfemoral TAVR and alternative‐access TAVR, patients who underwent transfemoral TAVR (n=49) had a similar good outcome as the patients who underwent SAVR (Figure <xref rid="jah35745-fig-0002" ref-type="fig">2B</xref>; crude HR, 0.43 [95% CI, 0.23–0.77], <italic>P</italic>=0.005; and crude HR, 0.32 [95% CI, 0.22–0.48], <italic>P</italic>&lt;0.001, respectively, versus ConsRx), whereas patients who underwent alternative access TAVR (n=48) had a worse survival, similar to the patients with ConsRx (HR, 0.94 [95% CI, 0.60–1.47]; <italic>P</italic>=0.80). After multivariate adjustment in the nonweighted population, transfemoral TAVR appeared to be the best therapeutic option (Figure <xref rid="jah35745-fig-0002" ref-type="fig">2C</xref>), with an adjusted HR of 0.23 (95% CI, 0.12–0.43; <italic>P</italic>&lt;0.001), followed by SAVR (adjusted HR, 0.36 [95% CI, 0.23–0.56]; <italic>P</italic>&lt;0.001) and alternative access TAVR (adjusted HR, 0.51 [95% CI, 0.31–0.82]; <italic>P</italic>=0.007).</p>
                <fig fig-type="Figure" xml:lang="en" id="jah35745-fig-0002" orientation="portrait" position="float">
                  <label>Figure 2</label>
                  <caption>
                    <title>Survival benefit of surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) in low‐flow, low‐gradient aortic stenosis (LFLG AS) and pooled analysis of the different treatment modalities.</title>
                    <p>Standard Kaplan‐Meier survival curves for the 3 treatment modalities (<bold>A</bold>) and after splitting the TAVR group into trans femoral and alternative access subgroups (<bold>B</bold>). <bold>C</bold>, Adjusted Survival Curves for the Cox proportional hazards model. See Data <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S1</xref> for details about multivariate analysis. HR indicates hazard ratio.</p>
                  </caption>
                  <graphic id="nlm-graphic-3" xlink:href="JAH3-9-e017870-g002"/>
                </fig>
                <p>After IPTW, although most of the characteristics were balanced for each pair of treatment, there were residual differences (Table <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S4</xref> for SAVR versus ConsRx, Table <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S5</xref> for TAVR versus ConsRx, and Table <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S6</xref> for TAVR versus SAVR). SAVR (wHR, 0.36 [95% CI, 0.21–0.62]; <italic>P</italic>&lt;0.001; Figure <xref rid="jah35745-fig-0003" ref-type="fig">3A</xref>) and TAVR (wHR, 0.38 [95% CI, 0.22–0.64]; <italic>P</italic>&lt;0.001; Figure <xref rid="jah35745-fig-0003" ref-type="fig">3B</xref>) were confirmed as being associated with a better survival compared with ConsRx. Further adjustment for the residual differences (after IPWT) did not alter the results (adjusted wHR, 0.38 [95% CI, 0.22–0.65], <italic>P</italic>&lt;0.001 for SAVR versus ConsRx and adjusted wHR, 0.40 [95% CI, 0.18–0.88], <italic>P</italic>=0.02 for TAVR versus ConsRx). Outcome after TAVR was comparable to SAVR (wHR, 1.27 [95% CI, 0.64–2.55]; <italic>P</italic>=0.49; Figure <xref rid="jah35745-fig-0003" ref-type="fig">3C</xref>). However, after IPTW, the TAVR weighted group remained significantly older (SMD=36%), had a higher prevalence of peripheral artery disease (SMD=29%), had a much lower Duke activity status index (SMD=90%), and had a higher EuroSCORE II (SMD=50%). After adjusting for these residual differences, there was a trend toward superiority of TAVR (adjusted wHR, 0.56 [95% CI, 0.26–1.24]; <italic>P</italic>=0.16). When dichotomizing TAVR according to access route, transfemoral TAVR was associated with improved survival versus SAVR (Figure <xref rid="jah35745-fig-0003" ref-type="fig">3D</xref>; adjusted wHR, 0.28 [95% CI, 0.11–0.72]; <italic>P</italic>=0.008).</p>
                <fig fig-type="Figure" xml:lang="en" id="jah35745-fig-0003" orientation="portrait" position="float">
                  <label>Figure 3</label>
                  <caption>
                    <title>Survival benefit of surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) in low‐flow, low‐gradient aortic stenosis (LFLG AS) using inverse probability of treatment weighting (IPTW).</title>
                    <p>Pairwise treatment comparison using inverse probability weighting. <bold>A</bold>, SAVR vs conservative management (ConsRx). <bold>B</bold>, TAVR vs ConsRx. <bold>C</bold>, SAVR vs TAVR. <bold>D</bold>, SAVR vs TAVR, subdivided into trans femoral and alternative access groups. The survival curves are adjusted using IPTW. The weighted numbers at risk are simulated and are, thus, not shown (see Figure <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S1</xref> for the weights). Adjusted weighted hazard ratio (HR): adjusted for baseline differences that remained significant despite IPTW (Tables <xref rid="jah35745-sup-0001" ref-type="supplementary-material">S4, S5 and S6</xref>).</p>
                  </caption>
                  <graphic id="nlm-graphic-5" xlink:href="JAH3-9-e017870-g003"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="discussion" id="jah35745-sec-0017">
              <title>DISCUSSION</title>
              <p>This study, which includes the largest prospective cohort of patients with LFLG AS with the longest follow‐up, is the first to compare the association between the different therapeutic strategies (ie, SAVR, TAVR, and ConsRx) in the different types of LFLG AS (ie, classic or paradoxical LFLG). The main findings of this study are that early (&lt;3 months) AVR, compared with a strategy combining ConsRx or delayed AVR, is associated with an important survival benefit in both the classic and paradoxical subsets of LFLG AS and in both true‐severe and pseudo‐severe AS. The other important finding is that TAVR appears to provide the best therapeutic option in this high‐risk population with AS.</p>
              <sec id="jah35745-sec-0018">
                <title>Benefit of AVR in LFLG AS</title>
                <p>One of the important findings of this study is that both patients with TSAS and those with PSAS had poor outcome with ConsRx, but derived an important survival benefit with AVR. These findings are consistent with the concept that PSAS, which generally corresponds to moderate or moderate‐to‐severe AS, may be well tolerated by patients with normal left ventricular function and no heart failure but poorly tolerated by patients with heart failure and a low‐flow state.<xref rid="jah35745-bib-0022" ref-type="ref"><sup>22</sup></xref>
</p>
                <p>Classic LFLG AS is the heart failure with reduced LVEF form of AS, whereas paradoxical LFLG AS is the heart failure with preserved LVEF form of AS. These patients with heart failure may not tolerate the left ventricular pressure overload associated with AS, even if it is only moderate. van Gils et al reported that moderate AS is associated with poor outcomes in patients with reduced LVEF.<xref rid="jah35745-bib-0010" ref-type="ref"><sup>10</sup></xref> Mohty et al reported that prosthesis‐patient mismatch, which is equivalent to moderate residual AS, is associated with reduced survival following SAVR. We previously demonstrated the cutoff value of AVA<sub>Proj</sub> below which mortality is increased in patients with LFLG AS under ConsRx is 1.2 cm<sup>2</sup>, which is larger than the cutoff value for severe AS in the guidelines (&lt;1.0 cm<sup>2</sup>) and further suggests that moderate AS may be detrimental in these patients.<xref rid="jah35745-bib-0007" ref-type="ref"><sup>7</sup></xref>, <xref rid="jah35745-bib-0013" ref-type="ref"><sup>13</sup></xref>, <xref rid="jah35745-bib-0023" ref-type="ref"><sup>23</sup></xref> In the present study, the vast majority (87%) of patients who underwent dobutamine stress echocardiography had an AVA<sub>Proj</sub> &lt;1.2 cm<sup>2</sup>. The results of this study provide support for considering AVR at milder degree of AS severity in symptomatic patients with LFLG AS. For AVA<sub>Proj</sub>, the threshold appears to be close to 1.2 cm<sup>2</sup>, which corresponds to the upper range of moderate AS. However, Sato et al demonstrated that PSAS, as defined by AVA<sub>Proj</sub> &gt;1.0, predicted no survival benefit from AVR.<xref rid="jah35745-bib-0024" ref-type="ref"><sup>24</sup></xref> Further studies are needed to determine whether we should use lower cutoff values of aortic valve calcification score (than those recommended in the guidelines: 2000 arbitrary units in men and 1200 arbitrary units in women) to consider AVR in patients with LFLG AS. The benefit and safety of early TAVR in patients with moderate AS and systolic heart failure are currently being assessed in the TAVR UNLOAD (Transcatheter Aortic Valve Replacement to Unload the Left Ventricle in Patients With Advanced Heart Failure) trial.<xref rid="jah35745-bib-0025" ref-type="ref"><sup>25</sup></xref>
</p>
              </sec>
              <sec id="jah35745-sec-0019">
                <title>SAVR Versus TAVR for LFLG AS</title>
                <p>Patients with LFLG AS, and especially those with classic LFLG and no contractile or flow reserve on dobutamine stress echocardiography, are at increased risk of 30‐day mortality following SAVR.<xref rid="jah35745-bib-0026" ref-type="ref"><sup>26</sup></xref>, <xref rid="jah35745-bib-0027" ref-type="ref"><sup>27</sup></xref>, <xref rid="jah35745-bib-0028" ref-type="ref"><sup>28</sup></xref>, <xref rid="jah35745-bib-0029" ref-type="ref"><sup>29</sup></xref> Despite the relatively high mortality, several studies and meta‐analysis have shown that patients with classic or paradoxical LFLG severe AS derive a major survival benefit with AVR versus ConsRx.<xref rid="jah35745-bib-0030" ref-type="ref"><sup>30</sup></xref> In the present study, trans femoral TAVR appeared to confer similar survival as SAVR in univariate analysis (Figure <xref rid="jah35745-fig-0002" ref-type="fig">2B</xref>). However, given that baseline risk profile was generally worse in the TAVR versus SAVR group, the adjusted curves (Figure <xref rid="jah35745-fig-0002" ref-type="fig">2C</xref>) and the fully adjusted IPTW model suggested a possible superiority of TAVR (adjusted wHR, 0.56 [95% CI, 0.26–1.24]; <italic>P</italic>=0.16), especially with trans femoral access (adjusted wHR, 0.28 [95% CI, 0.11–0.72]; <italic>P</italic>=0.008) over SAVR. The less invasive nature of TAVR, and especially trans femoral TAVR, offers the opportunity to improve outcomes in patients with LFLG AS who are generally at high surgical risk. A post hoc analysis of the Placement of Aortic Transcatheter Valves (PARTNER) trial revealed that TAVR was associated with a major survival benefit versus ConsRx in LFLG patients with prohibitive surgical risk (cohort B) and had similar survival compared with SAVR in LFLG patients with high surgical risk.<xref rid="jah35745-bib-0031" ref-type="ref"><sup>31</sup></xref> In the TOPAS TAVI (Transcatheter Aortic Valve Implantation) registry, patients with classic LFLG AS had low 30‐day mortality and excellent 1‐year outcomes following TAVR, regardless of the presence or absence of flow reserve on dobutamine stress echocardiography.<xref rid="jah35745-bib-0032" ref-type="ref"><sup>32</sup></xref> The present study suggests that TAVR, and particularly transfemoral TAVR, might be superior to SAVR for the therapeutic management of both classic and paradoxical LFLG AS. Patients with LFLG have more extensive cardiac damage and more vulnerable left ventricular function and may thus benefit more from a less invasive procedure, such as transfemoral TAVR.</p>
              </sec>
              <sec id="jah35745-sec-0020">
                <title>Limitations and Strengths</title>
                <p>First, this nonrandomized study is subject to treatment allocation bias. To overcome this limitation and allow robust comparison of the different treatment strategies, we used an IPTW analysis.<xref rid="jah35745-bib-0033" ref-type="ref"><sup>33</sup></xref>, <xref rid="jah35745-bib-0034" ref-type="ref"><sup>34</sup></xref> We elected to use IPTW over propensity score matching because the latter method would have required the exclusion of a large number of unmatched patients. We also used Cox proportional regression adjustment as a secondary method, and both methods provided consistent results. However, the ability of IPTW to balance between TAVR and SAVR groups was limited given the small overlap between these 2 treatment groups. Unmeasured confounding factors may also have introduced an additional source of bias by influencing therapeutic decision making and outcome. One of such factors could be the newly developed frailty indexes, which have been reported to influence therapeutic decision making and patient outcome.<xref rid="jah35745-bib-0035" ref-type="ref"><sup>35</sup></xref> We tried to limit this source of bias by excluding patients with severe cardiac and noncardiac comorbidities who are usually considered unsuitable candidates for AVR. Second, the observed results in the PSAS or paradoxical LFLG subcohorts are subject to bias related to subgroup analysis because the IPTW model allowed for an adjustment for the initial management decision (AVR versus ConsRx), but not for the actual severity of AS nor for the type of LFLG AS. Hence, the observed benefit in the PSAS and paradoxical LFLG subgroups remains hypothesis generating. Third, we pooled classic and paradoxical LFLG AS. However, patients with classic LFLG are at increased surgical risk, whereas patients with paradoxical LFLG generally have an intermediate‐risk profile. Although we found no interaction between type (classic or paradoxical) of LFLG AS and AVR with mortality, further studies are needed to address the benefit of AVR separately in each subset.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="jah35745-sec-0021">
              <title>Conclusions</title>
              <p>In this large prospective series of LFLG AS, early AVR was associated with a major survival benefit compared with ConsRx in both classic and paradoxical LFLG AS and in both TSAS and PSAS. Our results also suggest that transfemoral TAVR might be the best approach in patients with LFLG AS. The potential benefit of AVR in the subset of patients with PSAS and the superiority of transfemoral TAVR in patients with LFLG AS need to be confirmed in future randomized trials.</p>
            </sec>
            <sec id="jah35745-sec-0022">
              <title>Sources of Funding</title>
              <p>This work was supported by a grant (No. MOP‐57445 for TOPAS‐II and Nos. MOP‐126072 and FDN‐143225 for TOPAS‐III) from the Canadian Institutes of Health Research, Ottawa, Ontario, Canada.</p>
            </sec>
            <sec sec-type="COI-statement" id="jah35745-sec-0023">
              <title>Disclosures</title>
              <p>Dr Dahou was supported by a fellowship grant from L'Agence de la santé et des services sociaux de la Capitale nationale‐ADLSSS, Québec, Québec, Canada. Dr Pibarot holds the Canada Research Chair in Valvular Heart Diseases, Canadian Institutes of Health Research. Dr Clavel is a scholar fellow from Fond de recherche du Québec en santé. The remaining authors have no disclosures to report.</p>
            </sec>
            <sec id="jah35745-sec-0024">
              <table-wrap id="jah35745-tbl-0001" xml:lang="en" content-type="Table" orientation="portrait" position="float">
                <label>Table 1</label>
                <caption>
                  <p>Baseline Characteristics of the Overall TOPAS Cohort and Comparison According to Type of Treatment</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <thead valign="top">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">Overall TOPAS Cohort (n=481)</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">ConsRx (n=207; 43%)</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">SAVR (n=176; 37%)</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">TAVR (n=98; 20%)</th>
                      <th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Year of inclusion</td>
                      <td align="left" rowspan="1" colspan="1">2009 (2006–2013)</td>
                      <td align="left" rowspan="1" colspan="1">2008 (2005–2012)</td>
                      <td align="left" rowspan="1" colspan="1">2009 (2005–2010)</td>
                      <td align="left" rowspan="1" colspan="1">2013 (2010–2014)</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="6" rowspan="1">Clinical data</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age, y</td>
                      <td align="left" rowspan="1" colspan="1">75±10</td>
                      <td align="left" rowspan="1" colspan="1">75±10<xref ref-type="fn" rid="jah35745-note-0004">*</xref>, <xref ref-type="fn" rid="jah35745-note-0005">
†
</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">71±10<xref ref-type="fn" rid="jah35745-note-0005"><sup>
†
</sup></xref>, <xref ref-type="fn" rid="jah35745-note-0006"><sup>
‡
</sup></xref>
</td>
                      <td align="left" rowspan="1" colspan="1">80±7<xref ref-type="fn" rid="jah35745-note-0004">*</xref>, <xref ref-type="fn" rid="jah35745-note-0006">
‡
</xref>
</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male sex, n (%)</td>
                      <td align="left" rowspan="1" colspan="1">341 (71)</td>
                      <td align="left" rowspan="1" colspan="1">158 (73)</td>
                      <td align="left" rowspan="1" colspan="1">127 (72)</td>
                      <td align="left" rowspan="1" colspan="1">64 (66)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.48</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>
</td>
                      <td align="left" rowspan="1" colspan="1">27.6±5.6</td>
                      <td align="left" rowspan="1" colspan="1">27.5±5.7</td>
                      <td align="left" rowspan="1" colspan="1">28.3±5.8<xref ref-type="fn" rid="jah35745-note-0005"><sup>†</sup></xref>
</td>
                      <td align="left" rowspan="1" colspan="1">26.5±4.7<xref ref-type="fn" rid="jah35745-note-0004">*</xref>
</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.03</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes mellitus, n (%)</td>
                      <td align="left" rowspan="1" colspan="1">165 (34)</td>
                      <td align="left" rowspan="1" colspan="1">71 (33)</td>
                      <td align="left" rowspan="1" colspan="1">61 (35)</td>
                      <td align="left" rowspan="1" colspan="1">36 (37)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.73</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension, n (%)</td>
                      <td align="left" rowspan="1" colspan="1">355 (74)</td>
                      <td align="left" rowspan="1" colspan="1">150 (73)</td>
                      <td align="left" rowspan="1" colspan="1">118 (67)</td>
                      <td align="left" rowspan="1" colspan="1">87 (90)</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hyperlipidemia, n (%)</td>
                      <td align="left" rowspan="1" colspan="1">331 (69)</td>
                      <td align="left" rowspan="1" colspan="1">134 (65)</td>
                      <td align="left" rowspan="1" colspan="1">125 (71)</td>
                      <td align="left" rowspan="1" colspan="1">72 (74)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.38</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Chronic kidney disease (ie, eGFR ≤60 mL/min), n (%)</td>
                      <td align="left" rowspan="1" colspan="1">136 (28)</td>
                      <td align="left" rowspan="1" colspan="1">51 (23)</td>
                      <td align="left" rowspan="1" colspan="1">39 (22)</td>
                      <td align="left" rowspan="1" colspan="1">47 (49)</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Chronic obstructive pulmonary disease, n (%)</td>
                      <td align="left" rowspan="1" colspan="1">120 (25)</td>
                      <td align="left" rowspan="1" colspan="1">43 (21)</td>
                      <td align="left" rowspan="1" colspan="1">46 (27)</td>
                      <td align="left" rowspan="1" colspan="1">35 (38)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.009</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous CABG, n (%)</td>
                      <td align="left" rowspan="1" colspan="1">124 (26)</td>
                      <td align="left" rowspan="1" colspan="1">52 (25)</td>
                      <td align="left" rowspan="1" colspan="1">27 (15)</td>
                      <td align="left" rowspan="1" colspan="1">45 (46)</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous myocardial infarction, n (%)</td>
                      <td align="left" rowspan="1" colspan="1">176 (37)</td>
                      <td align="left" rowspan="1" colspan="1">100 (46)</td>
                      <td align="left" rowspan="1" colspan="1">47 (27)</td>
                      <td align="left" rowspan="1" colspan="1">37 (38)</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Coronary artery disease, n (%)</td>
                      <td align="left" rowspan="1" colspan="1">295 (61)</td>
                      <td align="left" rowspan="1" colspan="1">110 (53)</td>
                      <td align="left" rowspan="1" colspan="1">63 (112)</td>
                      <td align="left" rowspan="1" colspan="1">73 (75)</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous stroke or transient ischemic attack, n (%)</td>
                      <td align="left" rowspan="1" colspan="1">69 (14)</td>
                      <td align="left" rowspan="1" colspan="1">30 (15)</td>
                      <td align="left" rowspan="1" colspan="1">22 (12)</td>
                      <td align="left" rowspan="1" colspan="1">17 (18)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.51</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">History of peripheral artery disease, n (%)</td>
                      <td align="left" rowspan="1" colspan="1">40 (8)</td>
                      <td align="left" rowspan="1" colspan="1">18 (9)</td>
                      <td align="left" rowspan="1" colspan="1">4 (2)</td>
                      <td align="left" rowspan="1" colspan="1">18 (19)</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Atrial fibrillation/flutter, n (%)</td>
                      <td align="left" rowspan="1" colspan="1">78 (16)</td>
                      <td align="left" rowspan="1" colspan="1">27 (13)</td>
                      <td align="left" rowspan="1" colspan="1">27 (15)</td>
                      <td align="left" rowspan="1" colspan="1">25 (27)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.011</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Heart rate, bpm</td>
                      <td align="left" rowspan="1" colspan="1">71±13</td>
                      <td align="left" rowspan="1" colspan="1">71±14</td>
                      <td align="left" rowspan="1" colspan="1">72±14</td>
                      <td align="left" rowspan="1" colspan="1">70±12</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.39</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Systolic/diastolic blood pressure, mm Hg</td>
                      <td align="left" rowspan="1" colspan="1">123±20/71±12</td>
                      <td align="left" rowspan="1" colspan="1">124±20/71±11<xref ref-type="fn" rid="jah35745-note-0005"><sup>†</sup></xref>
</td>
                      <td align="left" rowspan="1" colspan="1">122±20/73±12<xref ref-type="fn" rid="jah35745-note-0005"><sup>†</sup></xref>
</td>
                      <td align="left" rowspan="1" colspan="1">122±21/68±13<xref ref-type="fn" rid="jah35745-note-0004">*</xref>, <xref ref-type="fn" rid="jah35745-note-0006">
‡
</xref>
</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.56/0.004</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="6" rowspan="1">Symptoms and functional status</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">History of CHF, n (%)</td>
                      <td align="left" rowspan="1" colspan="1">250 (52)</td>
                      <td align="left" rowspan="1" colspan="1">115 (57)</td>
                      <td align="left" rowspan="1" colspan="1">83 (48)</td>
                      <td align="left" rowspan="1" colspan="1">56 (62)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.07</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous acute pulmonary edema, n (%)</td>
                      <td align="left" rowspan="1" colspan="1">84 (18)</td>
                      <td align="left" rowspan="1" colspan="1">30 (15)</td>
                      <td align="left" rowspan="1" colspan="1">34 (19)</td>
                      <td align="left" rowspan="1" colspan="1">20 (21)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.32</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Functional class, n (%)</td>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">I</td>
                      <td align="left" rowspan="1" colspan="1">43 (9)</td>
                      <td align="left" rowspan="1" colspan="1">34 (17)</td>
                      <td align="left" rowspan="1" colspan="1">9 (5)</td>
                      <td align="left" rowspan="1" colspan="1">0 (0)</td>
                      <td align="char" char="." rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">II</td>
                      <td align="left" rowspan="1" colspan="1">173 (36)</td>
                      <td align="left" rowspan="1" colspan="1">84 (41)</td>
                      <td align="left" rowspan="1" colspan="1">61 (35)</td>
                      <td align="left" rowspan="1" colspan="1">28 (29)</td>
                      <td align="char" char="." rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">III</td>
                      <td align="left" rowspan="1" colspan="1">216 (45)</td>
                      <td align="left" rowspan="1" colspan="1">71 (35)</td>
                      <td align="left" rowspan="1" colspan="1">88 (51)</td>
                      <td align="left" rowspan="1" colspan="1">57 (59)</td>
                      <td align="char" char="." rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">IV</td>
                      <td align="left" rowspan="1" colspan="1">44 (9)</td>
                      <td align="left" rowspan="1" colspan="1">16 (8)</td>
                      <td align="left" rowspan="1" colspan="1">16 (9)</td>
                      <td align="left" rowspan="1" colspan="1">12 (12)</td>
                      <td align="char" char="." rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Duke activity status index</td>
                      <td align="left" rowspan="1" colspan="1">19 (10–31)</td>
                      <td align="left" rowspan="1" colspan="1">24 (13–38)<xref ref-type="fn" rid="jah35745-note-0004">*</xref>, <xref ref-type="fn" rid="jah35745-note-0005">
†
</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">19 (13–29)<xref ref-type="fn" rid="jah35745-note-0005"><sup>
†
</sup></xref>, <xref ref-type="fn" rid="jah35745-note-0006"><sup>
‡
</sup></xref>
</td>
                      <td align="left" rowspan="1" colspan="1">10 (7–16)<xref ref-type="fn" rid="jah35745-note-0004">*</xref>, <xref ref-type="fn" rid="jah35745-note-0006">
‡
</xref>
</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="6" rowspan="1">Aortic valve hemodynamics</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aortic valve area, cm<sup>2</sup>
</td>
                      <td align="left" rowspan="1" colspan="1">0.81±0.22</td>
                      <td align="left" rowspan="1" colspan="1">0.88±0.24<xref ref-type="fn" rid="jah35745-note-0004">*</xref>, <xref ref-type="fn" rid="jah35745-note-0005">
†
</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">0.76±0.17<xref ref-type="fn" rid="jah35745-note-0006"><sup>‡</sup></xref>
</td>
                      <td align="left" rowspan="1" colspan="1">0.76±0.22<xref ref-type="fn" rid="jah35745-note-0006"><sup>‡</sup></xref>
</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Indexed aortic valve area, cm<sup>2</sup>/m<sup>2</sup>
</td>
                      <td align="left" rowspan="1" colspan="1">0.43±0.12</td>
                      <td align="left" rowspan="1" colspan="1">0.47±0.13<xref ref-type="fn" rid="jah35745-note-0004">*</xref>, <xref ref-type="fn" rid="jah35745-note-0005">
†
</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">0.40±0.09<xref ref-type="fn" rid="jah35745-note-0006"><sup>‡</sup></xref>
</td>
                      <td align="left" rowspan="1" colspan="1">0.42±0.11<xref ref-type="fn" rid="jah35745-note-0006"><sup>‡</sup></xref>
</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean gradient, mm Hg</td>
                      <td align="left" rowspan="1" colspan="1">26±9</td>
                      <td align="left" rowspan="1" colspan="1">23±9<xref ref-type="fn" rid="jah35745-note-0004">*</xref>, <xref ref-type="fn" rid="jah35745-note-0005">
†
</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">28±8<xref ref-type="fn" rid="jah35745-note-0006"><sup>‡</sup></xref>
</td>
                      <td align="left" rowspan="1" colspan="1">27±8<xref ref-type="fn" rid="jah35745-note-0006"><sup>‡</sup></xref>
</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Peak aortic jet velocity, m/s</td>
                      <td align="left" rowspan="1" colspan="1">3.3 (2.9–3.7)</td>
                      <td align="left" rowspan="1" colspan="1">3.1±1.9<xref ref-type="fn" rid="jah35745-note-0004">*</xref>, <xref ref-type="fn" rid="jah35745-note-0005">
†
</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">3.5±1.8<xref ref-type="fn" rid="jah35745-note-0006"><sup>‡</sup></xref>
</td>
                      <td align="left" rowspan="1" colspan="1">3.4±1.8<xref ref-type="fn" rid="jah35745-note-0006"><sup>‡</sup></xref>
</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="6" rowspan="1">True AS severity</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Adjudicated true severe AS, n/n<sub>available</sub> (%)</td>
                      <td align="left" rowspan="1" colspan="1">293/425 (69)</td>
                      <td align="left" rowspan="1" colspan="1">86/172 (50)</td>
                      <td align="left" rowspan="1" colspan="1">145/169 (86)</td>
                      <td align="left" rowspan="1" colspan="1">62/84 (74)</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">AVA<sub>Proj</sub>, cm<sup>2</sup>
</td>
                      <td align="left" rowspan="1" colspan="1">0.99±0.21</td>
                      <td align="left" rowspan="1" colspan="1">1.05±0.2<xref ref-type="fn" rid="jah35745-note-0004">*</xref>, <xref ref-type="fn" rid="jah35745-note-0005">
†
</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">0.92±0.19<xref ref-type="fn" rid="jah35745-note-0006"><sup>‡</sup></xref>
</td>
                      <td align="left" rowspan="1" colspan="1">0.89±0.16<xref ref-type="fn" rid="jah35745-note-0006"><sup>‡</sup></xref>
</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">AVA<sub>Proj</sub> ≤1.0 cm<sup>2</sup>, n/n<sub>available</sub> (%)</td>
                      <td align="left" rowspan="1" colspan="1">121/206 (59)</td>
                      <td align="left" rowspan="1" colspan="1">53/118 (45)</td>
                      <td align="left" rowspan="1" colspan="1">48/64 (75)</td>
                      <td align="left" rowspan="1" colspan="1">20/24 (83)</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Aortic valve calcification ratio<xref ref-type="fn" rid="jah35745-note-0007"><sup>§</sup></xref>
</td>
                      <td align="left" rowspan="1" colspan="1">1.20±0.68</td>
                      <td align="left" rowspan="1" colspan="1">1.04±0.66</td>
                      <td align="left" rowspan="1" colspan="1">1.26±0.62</td>
                      <td align="left" rowspan="1" colspan="1">1.38±0.69<xref ref-type="fn" rid="jah35745-note-0006"><sup>‡</sup></xref>
</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.01</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Aortic valve calcification ratio ≥1.0, n/n<sub>available</sub> (%)</td>
                      <td align="left" rowspan="1" colspan="1">88/154 (57)</td>
                      <td align="left" rowspan="1" colspan="1">29/65 (45)</td>
                      <td align="left" rowspan="1" colspan="1">20/27 (74)</td>
                      <td align="left" rowspan="1" colspan="1">39/62 (63)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.02</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Aortic valve weight ratio<xref ref-type="fn" rid="jah35745-note-0007"><sup>§</sup></xref>
</td>
                      <td align="left" rowspan="1" colspan="1">1.25±0.45</td>
                      <td align="left" rowspan="1" colspan="1">NA</td>
                      <td align="left" rowspan="1" colspan="1">1.25±0.45</td>
                      <td align="left" rowspan="1" colspan="1">NA</td>
                      <td align="char" char="." rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Aortic valve weight ratio ≥1.0, n/n<sub>available</sub> (%)</td>
                      <td align="left" rowspan="1" colspan="1">72/106 (68)</td>
                      <td align="left" rowspan="1" colspan="1">NA</td>
                      <td align="left" rowspan="1" colspan="1">72/106 (68)</td>
                      <td align="left" rowspan="1" colspan="1">NA</td>
                      <td align="char" char="." rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Macroscopic assessment of surgically explanted valve, n/n<sub>available</sub> (%)</td>
                      <td align="left" rowspan="1" colspan="1">91/131 (70)</td>
                      <td align="left" rowspan="1" colspan="1">NA</td>
                      <td align="left" rowspan="1" colspan="1">91/131 (70)</td>
                      <td align="left" rowspan="1" colspan="1">NA</td>
                      <td align="char" char="." rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Indeterminate AS severity, n (%)</td>
                      <td align="left" rowspan="1" colspan="1">56 (12)</td>
                      <td align="left" rowspan="1" colspan="1">35 (17)</td>
                      <td align="left" rowspan="1" colspan="1">8 (5)</td>
                      <td align="left" rowspan="1" colspan="1">13 (13)</td>
                      <td align="char" char="." rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" colspan="6" rowspan="1">Left ventricular function</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stroke volume index, mL/m<sup>2</sup>
</td>
                      <td align="left" rowspan="1" colspan="1">31 (26–34)</td>
                      <td align="left" rowspan="1" colspan="1">32 (26–37)<xref ref-type="fn" rid="jah35745-note-0004">*</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">30 (27–33)<xref ref-type="fn" rid="jah35745-note-0006"><sup>‡</sup></xref>
</td>
                      <td align="left" rowspan="1" colspan="1">30 (24–33)<xref ref-type="fn" rid="jah35745-note-0006"><sup>‡</sup></xref>
</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.04</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">LVEF, %</td>
                      <td align="left" rowspan="1" colspan="1">38±17</td>
                      <td align="left" rowspan="1" colspan="1">32 (25–43)<xref ref-type="fn" rid="jah35745-note-0004">*</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">35 (25–60)<xref ref-type="fn" rid="jah35745-note-0005"><sup>
†
</sup></xref>, <xref ref-type="fn" rid="jah35745-note-0006"><sup>
‡
</sup></xref>
</td>
                      <td align="left" rowspan="1" colspan="1">30 (25–40)<xref ref-type="fn" rid="jah35745-note-0004">*</xref>
</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.06</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Indexed LVEDD, mm/m<sup>2</sup>
</td>
                      <td align="left" rowspan="1" colspan="1">29 (25–32)</td>
                      <td align="left" rowspan="1" colspan="1">30 (26–35)<xref ref-type="fn" rid="jah35745-note-0004">*</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">28 (24–31)<xref ref-type="fn" rid="jah35745-note-0006"><sup>‡</sup></xref>
</td>
                      <td align="left" rowspan="1" colspan="1">29 (26–32)</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Classic/paradoxical LFLG, n (%)</td>
                      <td align="left" rowspan="1" colspan="1">344 (72)/137 (28)</td>
                      <td align="left" rowspan="1" colspan="1">155 (75)/52 (25)</td>
                      <td align="left" rowspan="1" colspan="1">115 (65)/61 (35)</td>
                      <td align="left" rowspan="1" colspan="1">74 (76)/24 (24)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.07</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mitral regurgitation, n (%)</td>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="char" char="." rowspan="1" colspan="1">0.56</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">None</td>
                      <td align="left" rowspan="1" colspan="1">61 (34)</td>
                      <td align="left" rowspan="1" colspan="1">79 (38)</td>
                      <td align="left" rowspan="1" colspan="1">49 (28)</td>
                      <td align="left" rowspan="1" colspan="1">33 (34)</td>
                      <td align="char" char="." rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mild</td>
                      <td align="left" rowspan="1" colspan="1">269 (56)</td>
                      <td align="left" rowspan="1" colspan="1">108 (62)</td>
                      <td align="left" rowspan="1" colspan="1">112 (63)</td>
                      <td align="left" rowspan="1" colspan="1">49 (50)</td>
                      <td align="char" char="." rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Moderate</td>
                      <td align="left" rowspan="1" colspan="1">48 (10)</td>
                      <td align="left" rowspan="1" colspan="1">20 (12)</td>
                      <td align="left" rowspan="1" colspan="1">16 (9)</td>
                      <td align="left" rowspan="1" colspan="1">12 (16)</td>
                      <td align="char" char="." rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Severe</td>
                      <td align="left" rowspan="1" colspan="1">0 (0)</td>
                      <td align="left" rowspan="1" colspan="1">0 (0)</td>
                      <td align="left" rowspan="1" colspan="1">0 (0)</td>
                      <td align="left" rowspan="1" colspan="1">0 (0)</td>
                      <td align="char" char="." rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Systolic pulmonary artery pressure, mm Hg</td>
                      <td align="left" rowspan="1" colspan="1">43±13</td>
                      <td align="left" rowspan="1" colspan="1">43±13</td>
                      <td align="left" rowspan="1" colspan="1">42±13</td>
                      <td align="left" rowspan="1" colspan="1">43±14</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.95</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">NT‐proBNP, pg/mL</td>
                      <td align="left" rowspan="1" colspan="1">2304 (827–4771)</td>
                      <td align="left" rowspan="1" colspan="1">1526 (541–4269)<xref ref-type="fn" rid="jah35745-note-0005"><sup>†</sup></xref>
</td>
                      <td align="left" rowspan="1" colspan="1">2455 (829–4888)</td>
                      <td align="left" rowspan="1" colspan="1">2616 (1396–5182)<xref ref-type="fn" rid="jah35745-note-0006"><sup>‡</sup></xref>
</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.02</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="6" rowspan="1">Operative risk</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">EuroSCORE II, %</td>
                      <td align="left" rowspan="1" colspan="1">5.1 (2.3–8.7)</td>
                      <td align="left" rowspan="1" colspan="1">4.9 (2.4–8.0)<xref ref-type="fn" rid="jah35745-note-0004">*</xref>, <xref ref-type="fn" rid="jah35745-note-0005">
†
</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">3.1 (1.7–6.1)<xref ref-type="fn" rid="jah35745-note-0005"><sup>
†
</sup></xref>, <xref ref-type="fn" rid="jah35745-note-0006"><sup>
‡
</sup></xref>
</td>
                      <td align="left" rowspan="1" colspan="1">9.6 (7.0–15.2)<xref ref-type="fn" rid="jah35745-note-0004">*</xref>, <xref ref-type="fn" rid="jah35745-note-0006">
‡
</xref>
</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="jah35745-ntgp-0002">
                  <fn id="jah35745-note-0003">
                    <p>Values are mean±SD, median (interquartile range), and number (percentage). <italic>P</italic> value is for the ANOVA between treatment groups. AS indicates aortic stenosis; AVA<sub>Proj</sub>, projected aortic valve area at normal flow (ie, mean systolic flow rate 250 mL/s); bpm, beats per minute; CABG, coronary artery bypass grafting; CHF, congestive heart failure; ConsRx, conservative management; eGFR, estimated glomerular filtration rate; LVEDD, left ventricular end diastolic diameter; LFLG, low flow, low gradient; LVEF, left ventricular ejection fraction; NA: not applicable; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; and TOPAS, True or Pseudo Severe Aortic Stenosis.</p>
                  </fn>
                  <fn id="jah35745-note-0004">
                    <label>*</label>
                    <p>Post hoc <italic>P</italic>&lt;0.05 vs SAVR.</p>
                  </fn>
                  <fn id="jah35745-note-0005">
                    <label>
                      <sup>†</sup>
                    </label>
                    <p>Post hoc <italic>P</italic>&lt;0.05 vs TAVR.</p>
                  </fn>
                  <fn id="jah35745-note-0006">
                    <label>
                      <sup>‡</sup>
                    </label>
                    <p>Post hoc <italic>P</italic>&lt;0.05 vs ConsRx.</p>
                  </fn>
                  <fn id="jah35745-note-0007">
                    <label>
                      <sup>§</sup>
                    </label>
                    <p>Aortic valve calcification ratio was calculated by dividing the actual aortic valve calcium score by the sex‐specific threshold that defines severe AS (ie, 1200 and 2000 arbitrary units for women and men, respectively). Similarly, aortic valve weight ratio is the actual valve weight divided by the sex‐specific valve weight that defines true severe AS (ie, 1.2 and 2.0 g for women and men, respectively).<xref rid="jah35745-bib-0020" ref-type="ref"><sup>20</sup></xref>
</p>
                  </fn>
                </table-wrap-foot>
                <permissions>
                  <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                </permissions>
              </table-wrap>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="jah35745-sup-0001">
                <caption>
                  <p>
                    <bold>Data S1</bold>
                  </p>
                  <p>
                    <bold>Tables S1–S6</bold>
                  </p>
                  <p>
                    <bold>Figures S1–S4</bold>
                  </p>
                  <p><bold>References</bold><xref rid="jah35745-bib-0036" ref-type="ref"><bold>36</bold></xref>, <xref rid="jah35745-bib-0037" ref-type="ref"><bold>37</bold></xref></p>
                </caption>
                <media xlink:href="JAH3-9-e017870-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ref-list content-type="cited-references" id="jah35745-bibl-0001">
              <title>REFERENCES</title>
              <ref id="jah35745-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0001"><string-name><surname>Minners</surname><given-names>J</given-names></string-name>, <string-name><surname>Allgeier</surname><given-names>M</given-names></string-name>, <string-name><surname>Gohlke‐Baerwolf</surname><given-names>C</given-names></string-name>, <string-name><surname>Kienzle</surname><given-names>RP</given-names></string-name>, <string-name><surname>Neumann</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Jander</surname><given-names>N</given-names></string-name>. <article-title>Inconsistent grading of aortic valve stenosis by current guidelines: haemodynamic studies in patients with apparently normal left ventricular function</article-title>. <source xml:lang="en">Heart</source>. <year>2010</year>;<volume>96</volume>:<fpage>1463</fpage>–<lpage>1468</lpage>.<pub-id pub-id-type="pmid">20813727</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0002"><string-name><surname>Minners</surname><given-names>J</given-names></string-name>, <string-name><surname>Allgeier</surname><given-names>M</given-names></string-name>, <string-name><surname>Gohlke‐Baerwolf</surname><given-names>C</given-names></string-name>, <string-name><surname>Kienzle</surname><given-names>RP</given-names></string-name>, <string-name><surname>Neumann</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Jander</surname><given-names>N</given-names></string-name>. <article-title>Inconsistencies of echocardiographic criteria for the grading of aortic valve stenosis</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2008</year>;<volume>29</volume>:<fpage>1043</fpage>–<lpage>1048</lpage>.<pub-id pub-id-type="pmid">18156619</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0003"><string-name><surname>Clavel</surname><given-names>MA</given-names></string-name>, <string-name><surname>Magne</surname><given-names>J</given-names></string-name>, <string-name><surname>Pibarot</surname><given-names>P</given-names></string-name>. <article-title>Low‐gradient aortic stenosis</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2016</year>;<volume>37</volume>:<fpage>2645</fpage>–<lpage>2657</lpage>.<pub-id pub-id-type="pmid">27190103</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0004"><string-name><surname>Baumgartner</surname><given-names>H</given-names></string-name>, <string-name><surname>Falk</surname><given-names>V</given-names></string-name>, <string-name><surname>Bax</surname><given-names>JJ</given-names></string-name>, <string-name><surname>De Bonis</surname><given-names>M</given-names></string-name>, <string-name><surname>Hamm</surname><given-names>C</given-names></string-name>, <string-name><surname>Holm</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Iung</surname><given-names>B</given-names></string-name>, <string-name><surname>Lancellotti</surname><given-names>P</given-names></string-name>, <string-name><surname>Lansac</surname><given-names>E</given-names></string-name>, <string-name><surname>Munoz</surname><given-names>DR</given-names></string-name>, et al. <article-title>2017 ESC/EACTS guidelines for the management of valvular heart disease: the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio‐Thoracic Surgery (EACTS)</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2017</year>;<volume>38</volume>:<fpage>2739</fpage>–<lpage>2791</lpage>.<pub-id pub-id-type="pmid">28886619</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0005"><string-name><surname>Nishimura</surname><given-names>RA</given-names></string-name>, <string-name><surname>Otto</surname><given-names>CM</given-names></string-name>, <string-name><surname>Bonow</surname><given-names>RO</given-names></string-name>, <string-name><surname>Carabello</surname><given-names>BA</given-names></string-name>, <string-name><surname>Erwin</surname><given-names>JP</given-names><suffix>III</suffix></string-name>, <string-name><surname>Fleisher</surname><given-names>LA</given-names></string-name>, <string-name><surname>Jneid</surname><given-names>H</given-names></string-name>, <string-name><surname>Mack</surname><given-names>MJ</given-names></string-name>, <string-name><surname>McLeod</surname><given-names>CJ</given-names></string-name>, <string-name><surname>O'Gara</surname><given-names>PT</given-names></string-name>, et al. <article-title>2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2017</year>;<volume>70</volume>:<fpage>252</fpage>–<lpage>289</lpage>.<pub-id pub-id-type="pmid">28315732</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0006"><string-name><surname>Nishimura</surname><given-names>RA</given-names></string-name>, <string-name><surname>Otto</surname><given-names>CM</given-names></string-name>, <string-name><surname>Bonow</surname><given-names>RO</given-names></string-name>, <string-name><surname>Carabello</surname><given-names>BA</given-names></string-name>, <string-name><surname>Erwin</surname><given-names>JP</given-names><suffix>III</suffix></string-name>, <string-name><surname>Fleisher</surname><given-names>LA</given-names></string-name>, <string-name><surname>Jneid</surname><given-names>H</given-names></string-name>, <string-name><surname>Mack</surname><given-names>MJ</given-names></string-name>, <string-name><surname>McLeod</surname><given-names>CJ</given-names></string-name>, <string-name><surname>O'Gara</surname><given-names>PT</given-names></string-name>, et al. <article-title>2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines</article-title>. <source xml:lang="en">Circulation</source>. <year>2017</year>;<volume>135</volume>:<fpage>e1159</fpage>–<lpage>e1195</lpage>.<pub-id pub-id-type="pmid">28298458</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0007"><string-name><surname>Annabi</surname><given-names>MS</given-names></string-name>, <string-name><surname>Touboul</surname><given-names>E</given-names></string-name>, <string-name><surname>Dahou</surname><given-names>A</given-names></string-name>, <string-name><surname>Burwash</surname><given-names>IG</given-names></string-name>, <string-name><surname>Bergler‐Klein</surname><given-names>J</given-names></string-name>, <string-name><surname>Enriquez‐Sarano</surname><given-names>M</given-names></string-name>, <string-name><surname>Orwat</surname><given-names>S</given-names></string-name>, <string-name><surname>Baumgartner</surname><given-names>H</given-names></string-name>, <string-name><surname>Mascherbauer</surname><given-names>J</given-names></string-name>, <string-name><surname>Mundigler</surname><given-names>G</given-names></string-name>, et al. <article-title>Dobutamine stress echocardiography for management of low‐flow, low‐gradient aortic stenosis</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2018</year>;<volume>71</volume>:<fpage>475</fpage>–<lpage>485</lpage>.<pub-id pub-id-type="pmid">29406851</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0008"><string-name><surname>Clavel</surname><given-names>MA</given-names></string-name>, <string-name><surname>Messika‐Zeitoun</surname><given-names>D</given-names></string-name>, <string-name><surname>Pibarot</surname><given-names>P</given-names></string-name>, <string-name><surname>Aggarwal</surname><given-names>S</given-names></string-name>, <string-name><surname>Malouf</surname><given-names>J</given-names></string-name>, <string-name><surname>Araoz</surname><given-names>P</given-names></string-name>, <string-name><surname>Michelena</surname><given-names>H</given-names></string-name>, <string-name><surname>Cueff</surname><given-names>C</given-names></string-name>, <string-name><surname>Larose</surname><given-names>É</given-names></string-name>, <string-name><surname>Capoulade</surname><given-names>R</given-names></string-name>, et al. <article-title>The complex nature of discordant severe calcified aortic valve disease grading: new insights from combined doppler‐echocardiographic and computed tomographic study</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2013</year>;<volume>62</volume>:<fpage>2329</fpage>–<lpage>2338</lpage>.<pub-id pub-id-type="pmid">24076528</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0009"><string-name><surname>Fischer‐Rasokat</surname><given-names>U</given-names></string-name>, <string-name><surname>Renker</surname><given-names>M</given-names></string-name>, <string-name><surname>Liebetrau</surname><given-names>C</given-names></string-name>, <string-name><surname>van Linden</surname><given-names>A</given-names></string-name>, <string-name><surname>Arsalan</surname><given-names>M</given-names></string-name>, <string-name><surname>Weferling</surname><given-names>M</given-names></string-name>, <string-name><surname>Rolf</surname><given-names>A</given-names></string-name>, <string-name><surname>Doss</surname><given-names>M</given-names></string-name>, <string-name><surname>Mollmann</surname><given-names>H</given-names></string-name>, <string-name><surname>Walther</surname><given-names>T</given-names></string-name>, et al. <article-title>1‐Year survival after TAVR of patients with low‐flow, low‐gradient and high‐gradient aortic valve stenosis in matched study populations</article-title>. <source xml:lang="en">JACC Cardiovasc Interv</source>. <year>2019</year>;<volume>12</volume>:<fpage>752</fpage>–<lpage>763</lpage>.<pub-id pub-id-type="pmid">31000012</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0010"><string-name><surname>van Gils</surname><given-names>L</given-names></string-name>, <string-name><surname>Clavel</surname><given-names>MA</given-names></string-name>, <string-name><surname>Vollema</surname><given-names>EM</given-names></string-name>, <string-name><surname>Hahn</surname><given-names>RT</given-names></string-name>, <string-name><surname>Spitzer</surname><given-names>E</given-names></string-name>, <string-name><surname>Delgado</surname><given-names>V</given-names></string-name>, <string-name><surname>Nazif</surname><given-names>T</given-names></string-name>, <string-name><surname>De Jaegere</surname><given-names>PP</given-names></string-name>, <string-name><surname>Geleijnse</surname><given-names>ML</given-names></string-name>, <string-name><surname>Ben‐Yehuda</surname><given-names>O</given-names></string-name>, et al. <article-title>Prognostic implications of moderate aortic stenosis in patients with left ventricular systolic dysfunction</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2017</year>;<volume>69</volume>:<fpage>2383</fpage>–<lpage>2392</lpage>.<pub-id pub-id-type="pmid">28494976</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0011"><string-name><surname>Samad</surname><given-names>Z</given-names></string-name>, <string-name><surname>Vora</surname><given-names>AN</given-names></string-name>, <string-name><surname>Dunning</surname><given-names>A</given-names></string-name>, <string-name><surname>Schulte</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Shaw</surname><given-names>LK</given-names></string-name>, <string-name><surname>Al‐Enezi</surname><given-names>F</given-names></string-name>, <string-name><surname>Ersboll</surname><given-names>M</given-names></string-name>, <string-name><surname>McGarrah</surname><given-names>RW</given-names><suffix>III</suffix></string-name>, <string-name><surname>Vavalle</surname><given-names>JP</given-names></string-name>, <string-name><surname>Shah</surname><given-names>SH</given-names></string-name>, et al. <article-title>Aortic valve surgery and survival in patients with moderate or severe aortic stenosis and left ventricular dysfunction</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2016</year>;<volume>37</volume>:<fpage>2276</fpage>–<lpage>2286</lpage>.<pub-id pub-id-type="pmid">26787441</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0012"><string-name><surname>Blais</surname><given-names>C</given-names></string-name>, <string-name><surname>Burwash</surname><given-names>IG</given-names></string-name>, <string-name><surname>Mundigler</surname><given-names>G</given-names></string-name>, <string-name><surname>Dumesnil</surname><given-names>JG</given-names></string-name>, <string-name><surname>Loho</surname><given-names>N</given-names></string-name>, <string-name><surname>Rader</surname><given-names>F</given-names></string-name>, <string-name><surname>Baumgartner</surname><given-names>H</given-names></string-name>, <string-name><surname>Beanlands</surname><given-names>RS</given-names></string-name>, <string-name><surname>Chayer</surname><given-names>B</given-names></string-name>, <string-name><surname>Kadem</surname><given-names>L</given-names></string-name>, et al. <article-title>Projected valve area at normal flow rate improves the assessment of stenosis severity in patients with low flow, low‐gradient aortic stenosis: the multicenter TOPAS (truly or pseudo severe aortic stenosis) study</article-title>. <source xml:lang="en">Circulation</source>. <year>2006</year>;<volume>113</volume>:<fpage>711</fpage>–<lpage>721</lpage>.<pub-id pub-id-type="pmid">16461844</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0013"><string-name><surname>Clavel</surname><given-names>MA</given-names></string-name>, <string-name><surname>Fuchs</surname><given-names>C</given-names></string-name>, <string-name><surname>Burwash</surname><given-names>IG</given-names></string-name>, <string-name><surname>Mundigler</surname><given-names>G</given-names></string-name>, <string-name><surname>Dumesnil</surname><given-names>JG</given-names></string-name>, <string-name><surname>Baumgartner</surname><given-names>H</given-names></string-name>, <string-name><surname>Bergler‐Klein</surname><given-names>J</given-names></string-name>, <string-name><surname>Beanlands</surname><given-names>RS</given-names></string-name>, <string-name><surname>Mathieu</surname><given-names>P</given-names></string-name>, <string-name><surname>Magne</surname><given-names>J</given-names></string-name>, et al. <article-title>Predictors of outcomes in low‐flow, low‐gradient aortic stenosis: results of the multicenter TOPAS Study</article-title>. <source xml:lang="en">Circulation</source>. <year>2008</year>;<volume>118</volume>:<fpage>S234</fpage>–<lpage>S242</lpage>.<pub-id pub-id-type="pmid">18824760</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0014"><string-name><surname>Dahou</surname><given-names>A</given-names></string-name>, <string-name><surname>Bartko</surname><given-names>PE</given-names></string-name>, <string-name><surname>Capoulade</surname><given-names>R</given-names></string-name>, <string-name><surname>Clavel</surname><given-names>MA</given-names></string-name>, <string-name><surname>Mundigler</surname><given-names>G</given-names></string-name>, <string-name><surname>Grondin</surname><given-names>SL</given-names></string-name>, <string-name><surname>Bergler‐Klein</surname><given-names>J</given-names></string-name>, <string-name><surname>Burwash</surname><given-names>I</given-names></string-name>, <string-name><surname>Dumesnil</surname><given-names>JG</given-names></string-name>, <string-name><surname>Senechal</surname><given-names>M</given-names></string-name>, et al. <article-title>Usefulness of global left ventricular longitudinal strain for risk stratification in low ejection fraction, low‐gradient aortic stenosis: results from the multicenter true or pseudo‐severe aortic stenosis study</article-title>. <source xml:lang="en">Circ Cardiovasc Imaging</source>. <year>2015</year>;<volume>8</volume>:<elocation-id>e002117</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCIMAGING.114.002117</pub-id>.<pub-id pub-id-type="pmid">25681417</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0015"><string-name><surname>Baumgartner</surname><given-names>H</given-names></string-name>, <string-name><surname>Hung</surname><given-names>J</given-names></string-name>, <string-name><surname>Bermejo</surname><given-names>J</given-names></string-name>, <string-name><surname>Chambers</surname><given-names>JB</given-names></string-name>, <string-name><surname>Evangelista</surname><given-names>A</given-names></string-name>, <string-name><surname>Griffin</surname><given-names>BP</given-names></string-name>, <string-name><surname>Iung</surname><given-names>B</given-names></string-name>, <string-name><surname>Otto</surname><given-names>CM</given-names></string-name>, <string-name><surname>Pellikka</surname><given-names>PA</given-names></string-name>, <string-name><surname>Quinones</surname><given-names>M</given-names></string-name>. <article-title>Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice</article-title>. <source xml:lang="en">J Am Soc Echocardiogr</source>. <year>2009</year>;<volume>22</volume>:<fpage>1</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">19130998</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0016"><string-name><surname>Lancellotti</surname><given-names>P</given-names></string-name>, <string-name><surname>Moura</surname><given-names>L</given-names></string-name>, <string-name><surname>Pierard</surname><given-names>LA</given-names></string-name>, <string-name><surname>Agricola</surname><given-names>E</given-names></string-name>, <string-name><surname>Popescu</surname><given-names>BA</given-names></string-name>, <string-name><surname>Tribouilloy</surname><given-names>C</given-names></string-name>, <string-name><surname>Hagendorff</surname><given-names>A</given-names></string-name>, <string-name><surname>Monin</surname><given-names>JL</given-names></string-name>, <string-name><surname>Badano</surname><given-names>L</given-names></string-name>, <string-name><surname>Zamorano</surname><given-names>JL</given-names></string-name>. <article-title>European Association of Echocardiography recommendations for the assessment of valvular regurgitation, part 2: mitral and tricuspid regurgitation (native valve disease)</article-title>. <source xml:lang="en">Eur J Echocardiogr</source>. <year>2010</year>;<volume>11</volume>:<fpage>307</fpage>–<lpage>332</lpage>.<pub-id pub-id-type="pmid">20435783</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0017"><string-name><surname>Lancellotti</surname><given-names>P</given-names></string-name>, <string-name><surname>Tribouilloy</surname><given-names>C</given-names></string-name>, <string-name><surname>Hagendorff</surname><given-names>A</given-names></string-name>, <string-name><surname>Moura</surname><given-names>L</given-names></string-name>, <string-name><surname>Popescu</surname><given-names>BA</given-names></string-name>, <string-name><surname>Agricola</surname><given-names>E</given-names></string-name>, <string-name><surname>Monin</surname><given-names>JL</given-names></string-name>, <string-name><surname>Pierard</surname><given-names>LA</given-names></string-name>, <string-name><surname>Badano</surname><given-names>L</given-names></string-name>, <string-name><surname>Zamorano</surname><given-names>JL</given-names></string-name>. <article-title>European Association of Echocardiography recommendations for the assessment of valvular regurgitation, part 1: aortic and pulmonary regurgitation (native valve disease)</article-title>. <source xml:lang="en">Eur J Echocardiogr</source>. <year>2010</year>;<volume>11</volume>:<fpage>223</fpage>–<lpage>244</lpage>.<pub-id pub-id-type="pmid">20375260</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0018"><string-name><surname>Pawade</surname><given-names>T</given-names></string-name>, <string-name><surname>Clavel</surname><given-names>MA</given-names></string-name>, <string-name><surname>Tribouilloy</surname><given-names>C</given-names></string-name>, <string-name><surname>Dreyfus</surname><given-names>J</given-names></string-name>, <string-name><surname>Mathieu</surname><given-names>T</given-names></string-name>, <string-name><surname>Tastet</surname><given-names>L</given-names></string-name>, <string-name><surname>Renard</surname><given-names>C</given-names></string-name>, <string-name><surname>Gun</surname><given-names>M</given-names></string-name>, <string-name><surname>Jenkins</surname><given-names>WSA</given-names></string-name>, <string-name><surname>Macron</surname><given-names>L</given-names></string-name>, et al. <article-title>Computed tomography aortic valve calcium scoring in patients with aortic stenosis</article-title>. <source xml:lang="en">Circ Cardiovasc Imaging</source>. <year>2018</year>;<volume>11</volume>:<elocation-id>e007146</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCIMAGING.117.007146</pub-id>.<pub-id pub-id-type="pmid">29555836</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0019"><string-name><surname>Clavel</surname><given-names>MA</given-names></string-name>, <string-name><surname>Burwash</surname><given-names>IG</given-names></string-name>, <string-name><surname>Mundigler</surname><given-names>G</given-names></string-name>, <string-name><surname>Dumesnil</surname><given-names>JG</given-names></string-name>, <string-name><surname>Baumgartner</surname><given-names>H</given-names></string-name>, <string-name><surname>Bergler‐Klein</surname><given-names>J</given-names></string-name>, <string-name><surname>Sénéchal</surname><given-names>M</given-names></string-name>, <string-name><surname>Mathieu</surname><given-names>P</given-names></string-name>, <string-name><surname>Couture</surname><given-names>C</given-names></string-name>, <string-name><surname>Beanlands</surname><given-names>R</given-names></string-name>, et al. <article-title>Validation of conventional and simplified methods to calculate projected valve area at normal flow rate in patients with low flow, low gradient aortic stenosis: the multicenter TOPAS (true or pseudo severe aortic stenosis) study</article-title>. <source xml:lang="en">J Am Soc Echocardiogr</source>. <year>2010</year>;<volume>23</volume>:<fpage>380</fpage>–<lpage>386</lpage>.<pub-id pub-id-type="pmid">20362927</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0020"><string-name><surname>Clavel</surname><given-names>MA</given-names></string-name>, <string-name><surname>Côté</surname><given-names>N</given-names></string-name>, <string-name><surname>Mathieu</surname><given-names>P</given-names></string-name>, <string-name><surname>Dumesnil</surname><given-names>JG</given-names></string-name>, <string-name><surname>Audet</surname><given-names>A</given-names></string-name>, <string-name><surname>Pépin</surname><given-names>A</given-names></string-name>, <string-name><surname>Couture</surname><given-names>C</given-names></string-name>, <string-name><surname>Fournier</surname><given-names>D</given-names></string-name>, <string-name><surname>Trahan</surname><given-names>S</given-names></string-name>, <string-name><surname>Pagé</surname><given-names>S</given-names></string-name>, et al. <article-title>Paradoxical low‐flow, low‐gradient aortic stenosis despite preserved left ventricular ejection fraction: new insights from weights of operatively excised aortic valves</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2014</year>;<volume>35</volume>:<fpage>2655</fpage>–<lpage>2662</lpage>.<pub-id pub-id-type="pmid">24755006</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0021"><string-name><surname>Cole</surname><given-names>SR</given-names></string-name>, <string-name><surname>Hernan</surname><given-names>MA</given-names></string-name>. <article-title>Adjusted survival curves with inverse probability weights</article-title>. <source xml:lang="en">Comput Methods Programs Biomed</source>. <year>2004</year>;<volume>75</volume>:<fpage>45</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">15158046</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0022"><string-name><surname>Pibarot</surname><given-names>P</given-names></string-name>, <string-name><surname>Messika‐Zeitoun</surname><given-names>D</given-names></string-name>, <string-name><surname>Ben‐Yehuda</surname><given-names>O</given-names></string-name>, <string-name><surname>Hahn</surname><given-names>RT</given-names></string-name>, <string-name><surname>Burwash</surname><given-names>IG</given-names></string-name>, <string-name><surname>Van Mieghem</surname><given-names>NM</given-names></string-name>, <string-name><surname>Spitzer</surname><given-names>E</given-names></string-name>, <string-name><surname>Leon</surname><given-names>MB</given-names></string-name>, <string-name><surname>Bax</surname><given-names>J</given-names></string-name>, <string-name><surname>Otto</surname><given-names>CM</given-names></string-name>. <article-title>Moderate aortic stenosis and heart failure with reduced ejection fraction: can imaging guide us to therapy?</article-title><source xml:lang="en">JACC Cardiovasc Imaging</source>. <year>2019</year>;<volume>12</volume>:<fpage>172</fpage>–<lpage>184</lpage>.<pub-id pub-id-type="pmid">30621989</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0023"><string-name><surname>Clavel</surname><given-names>MA</given-names></string-name>, <string-name><surname>Ennezat</surname><given-names>PV</given-names></string-name>, <string-name><surname>Maréchaux</surname><given-names>S</given-names></string-name>, <string-name><surname>Dumesnil</surname><given-names>JG</given-names></string-name>, <string-name><surname>Capoulade</surname><given-names>R</given-names></string-name>, <string-name><surname>Hachicha</surname><given-names>Z</given-names></string-name>, <string-name><surname>Mathieu</surname><given-names>P</given-names></string-name>, <string-name><surname>Bellouin</surname><given-names>A</given-names></string-name>, <string-name><surname>Bergeron</surname><given-names>S</given-names></string-name>, <string-name><surname>Meimoun</surname><given-names>P</given-names></string-name>, et al. <article-title>Stress echocardiography to assess stenosis severity and predict outcome in patients with paradoxical low‐flow, low‐gradient aortic stenosis and preserved LVEF</article-title>. <source xml:lang="en">JACC Cardiovasc Imaging</source>. <year>2013</year>;<volume>6</volume>:<fpage>175</fpage>–<lpage>183</lpage>.<pub-id pub-id-type="pmid">23489531</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0024"><string-name><surname>Sato</surname><given-names>K</given-names></string-name>, <string-name><surname>Sankaramangalam</surname><given-names>K</given-names></string-name>, <string-name><surname>Kandregula</surname><given-names>K</given-names></string-name>, <string-name><surname>Bullen</surname><given-names>J</given-names></string-name>, <string-name><surname>Kapadia</surname><given-names>SR</given-names></string-name>, <string-name><surname>Krishnaswamy</surname><given-names>A</given-names></string-name>, <string-name><surname>Mick</surname><given-names>S</given-names></string-name>, <string-name><surname>Rodriguez</surname><given-names>L</given-names></string-name>, <string-name><surname>Grimm</surname><given-names>RA</given-names></string-name>, <string-name><surname>Menon</surname><given-names>V</given-names></string-name>, et al. <article-title>Contemporary outcomes in low‐gradient aortic stenosis patients who underwent dobutamine stress echocardiography</article-title>. <source xml:lang="en">J Am Heart Assoc</source>. <year>2019</year>;<volume>8</volume>:<elocation-id>e011168</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/JAHA.118.011168</pub-id>.<pub-id pub-id-type="pmid">30879370</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0025"><string-name><surname>Spitzer</surname><given-names>E</given-names></string-name>, <string-name><surname>Van Mieghem</surname><given-names>NM</given-names></string-name>, <string-name><surname>Pibarot</surname><given-names>P</given-names></string-name>, <string-name><surname>Hahn</surname><given-names>RT</given-names></string-name>, <string-name><surname>Kodali</surname><given-names>S</given-names></string-name>, <string-name><surname>Maurer</surname><given-names>MS</given-names></string-name>, <string-name><surname>Nazif</surname><given-names>TM</given-names></string-name>, <string-name><surname>Rodés‐Cabau</surname><given-names>J</given-names></string-name>, <string-name><surname>Paradis</surname><given-names>JM</given-names></string-name>, <string-name><surname>Kappetein</surname><given-names>AP</given-names></string-name>, et al. <article-title>Rationale and design of the transcatheter aortic valve replacement to unload the left ventricle in patients with advanced heart failure (TAVR UNLOAD) trial</article-title>. <source xml:lang="en">Am Heart J</source>. <year>2016</year>;<volume>182</volume>:<fpage>80</fpage>–<lpage>88</lpage>.<pub-id pub-id-type="pmid">27914503</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0026"><string-name><surname>Monin</surname><given-names>JL</given-names></string-name>, <string-name><surname>Quere</surname><given-names>JP</given-names></string-name>, <string-name><surname>Monchi</surname><given-names>M</given-names></string-name>, <string-name><surname>Petit</surname><given-names>H</given-names></string-name>, <string-name><surname>Baleynaud</surname><given-names>S</given-names></string-name>, <string-name><surname>Chauvel</surname><given-names>C</given-names></string-name>, <string-name><surname>Pop</surname><given-names>C</given-names></string-name>, <string-name><surname>Ohlmann</surname><given-names>P</given-names></string-name>, <string-name><surname>Lelguen</surname><given-names>C</given-names></string-name>, <string-name><surname>Dehant</surname><given-names>P</given-names></string-name>, et al. <article-title>Low‐gradient aortic stenosis: operative risk stratification and predictors for long‐term outcome: a multicenter study using dobutamine stress hemodynamics</article-title>. <source xml:lang="en">Circulation</source>. <year>2003</year>;<volume>108</volume>:<fpage>319</fpage>–<lpage>324</lpage>.<pub-id pub-id-type="pmid">12835219</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0027"><string-name><surname>Tribouilloy</surname><given-names>C</given-names></string-name>, <string-name><surname>Levy</surname><given-names>F</given-names></string-name>, <string-name><surname>Rusinaru</surname><given-names>D</given-names></string-name>, <string-name><surname>Gueret</surname><given-names>P</given-names></string-name>, <string-name><surname>Petit‐Eisenmann</surname><given-names>H</given-names></string-name>, <string-name><surname>Baleynaud</surname><given-names>S</given-names></string-name>, <string-name><surname>Jobic</surname><given-names>Y</given-names></string-name>, <string-name><surname>Adams</surname><given-names>C</given-names></string-name>, <string-name><surname>Lelong</surname><given-names>B</given-names></string-name>, <string-name><surname>Pasquet</surname><given-names>A</given-names></string-name>, et al. <article-title>Outcome after aortic valve replacement for low‐flow/low‐gradient aortic stenosis without contractile reserve on dobutamine stress echocardiography</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2009</year>;<volume>53</volume>:<fpage>1865</fpage>–<lpage>1873</lpage>.<pub-id pub-id-type="pmid">19442886</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0028"><string-name><surname>Clavel</surname><given-names>MA</given-names></string-name>, <string-name><surname>Berthelot‐Richer</surname><given-names>M</given-names></string-name>, <string-name><surname>Le Ven</surname><given-names>F</given-names></string-name>, <string-name><surname>Capoulade</surname><given-names>R</given-names></string-name>, <string-name><surname>Dahou</surname><given-names>A</given-names></string-name>, <string-name><surname>Dumesnil</surname><given-names>JG</given-names></string-name>, <string-name><surname>Mathieu</surname><given-names>P</given-names></string-name>, <string-name><surname>Pibarot</surname><given-names>P</given-names></string-name>. <article-title>Impact of classic and paradoxical low flow on survival after aortic valve replacement for severe aortic stenosis</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2015</year>;<volume>65</volume>:<fpage>645</fpage>–<lpage>653</lpage>.<pub-id pub-id-type="pmid">25677424</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0029"><string-name><surname>Vahanian</surname><given-names>A</given-names></string-name>, <string-name><surname>Iung</surname><given-names>B</given-names></string-name>. <article-title>The new ESC/EACTS guidelines on the management of valvular heart disease</article-title>. <source xml:lang="en">Arch Cardiovasc Dis</source>. <year>2012</year>;<volume>105</volume>:<fpage>465</fpage>–<lpage>467</lpage>.<pub-id pub-id-type="pmid">23062477</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0030"><string-name><surname>Dayan</surname><given-names>V</given-names></string-name>, <string-name><surname>Vignolo</surname><given-names>G</given-names></string-name>, <string-name><surname>Magne</surname><given-names>J</given-names></string-name>, <string-name><surname>Clavel</surname><given-names>MA</given-names></string-name>, <string-name><surname>Mohty</surname><given-names>D</given-names></string-name>, <string-name><surname>Pibarot</surname><given-names>P</given-names></string-name>. <article-title>Outcome and impact of aortic valve replacement in patients with preserved LV ejection fraction and low gradient aortic stenosis: a meta‐analysis</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2015</year>;<volume>66</volume>:<fpage>2594</fpage>–<lpage>2603</lpage>.<pub-id pub-id-type="pmid">26670058</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0031"><string-name><surname>Herrmann</surname><given-names>HC</given-names></string-name>, <string-name><surname>Pibarot</surname><given-names>P</given-names></string-name>, <string-name><surname>Hueter</surname><given-names>I</given-names></string-name>, <string-name><surname>Gertz</surname><given-names>ZM</given-names></string-name>, <string-name><surname>Stewart</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Kapadia</surname><given-names>S</given-names></string-name>, <string-name><surname>Tuczu</surname><given-names>EM</given-names></string-name>, <string-name><surname>Babaliaros</surname><given-names>V</given-names></string-name>, <string-name><surname>Thourani</surname><given-names>V</given-names></string-name>, <string-name><surname>Szeto</surname><given-names>WY</given-names></string-name>, et al. <article-title>Predictors of mortality and outcomes of therapy in low flow severe aortic stenosis: a PARTNER trial analysis</article-title>. <source xml:lang="en">Circulation</source>. <year>2013</year>;<volume>127</volume>:<fpage>2316</fpage>–<lpage>2326</lpage>.<pub-id pub-id-type="pmid">23661722</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0032"><string-name><surname>Ribeiro</surname><given-names>HB</given-names></string-name>, <string-name><surname>Lerakis</surname><given-names>S</given-names></string-name>, <string-name><surname>Gilard</surname><given-names>M</given-names></string-name>, <string-name><surname>Cavalcante</surname><given-names>JL</given-names></string-name>, <string-name><surname>Makkar</surname><given-names>R</given-names></string-name>, <string-name><surname>Herrmann</surname><given-names>HC</given-names></string-name>, <string-name><surname>Windecker</surname><given-names>S</given-names></string-name>, <string-name><surname>Enriquez‐Sarano</surname><given-names>M</given-names></string-name>, <string-name><surname>Cheema</surname><given-names>AN</given-names></string-name>, <string-name><surname>Nombela‐Franco</surname><given-names>L</given-names></string-name>, et al. <article-title>Transcatheter aortic valve replacement in patients with low‐flow, low‐gradient aortic stenosis: the TOPAS‐TAVI Registry</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2018</year>;<volume>71</volume>:<fpage>1297</fpage>–<lpage>1308</lpage>.<pub-id pub-id-type="pmid">29566812</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0033"><string-name><surname>Austin</surname><given-names>PC</given-names></string-name>. <article-title>An introduction to propensity score methods for reducing the effects of confounding in observational studies</article-title>. <source xml:lang="en">Multivariate Behav Res</source>. <year>2011</year>;<volume>46</volume>:<fpage>399</fpage>–<lpage>424</lpage>.<pub-id pub-id-type="pmid">21818162</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0034"><string-name><surname>Austin</surname><given-names>PC</given-names></string-name>. <article-title>The performance of different propensity‐score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies</article-title>. <source xml:lang="en">Stat Med</source>. <year>2010</year>;<volume>29</volume>:<fpage>2137</fpage>–<lpage>2148</lpage>.<pub-id pub-id-type="pmid">20108233</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0035"><string-name><surname>Afilalo</surname><given-names>J</given-names></string-name>, <string-name><surname>Kim</surname><given-names>S</given-names></string-name>, <string-name><surname>O'Brien</surname><given-names>S</given-names></string-name>, <string-name><surname>Brennan</surname><given-names>JM</given-names></string-name>, <string-name><surname>Edwards</surname><given-names>FH</given-names></string-name>, <string-name><surname>Mack</surname><given-names>MJ</given-names></string-name>, <string-name><surname>McClurken</surname><given-names>JB</given-names></string-name>, <string-name><surname>Cleveland</surname><given-names>JC</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Smith</surname><given-names>PK</given-names></string-name>, <string-name><surname>Shahian</surname><given-names>DM</given-names></string-name>, et al. <article-title>Gait speed and operative mortality in older adults following cardiac surgery</article-title>. <source xml:lang="en">JAMA Cardiol</source>. <year>2016</year>;<volume>1</volume>:<fpage>314</fpage>–<lpage>321</lpage>.<pub-id pub-id-type="pmid">27438112</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0036"><string-name><surname>Lang</surname><given-names>RM</given-names></string-name>, <string-name><surname>Badano</surname><given-names>LP</given-names></string-name>, <string-name><surname>Mor‐Avi</surname><given-names>V</given-names></string-name>, <string-name><surname>Afilalo</surname><given-names>J</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>A</given-names></string-name>, <string-name><surname>Ernande</surname><given-names>L</given-names></string-name>, <string-name><surname>Flachskampf</surname><given-names>FA</given-names></string-name>, <string-name><surname>Foster</surname><given-names>E</given-names></string-name>, <string-name><surname>Goldstein</surname><given-names>SA</given-names></string-name>, <string-name><surname>Kuznetsova</surname><given-names>T</given-names></string-name>, et al. <article-title>Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging</article-title>. <source xml:lang="en">J Am Soc Echocardiogr</source>. <year>2015</year>;<volume>28</volume>:<fpage>1</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">25559473</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0037"><string-name><surname>Baumgartner</surname><given-names>H</given-names></string-name>, <string-name><surname>Hung</surname><given-names>J</given-names></string-name>, <string-name><surname>Bermejo</surname><given-names>J</given-names></string-name>, <string-name><surname>Chambers</surname><given-names>JB</given-names></string-name>, <string-name><surname>Edvardsen</surname><given-names>T</given-names></string-name>, <string-name><surname>Goldstein</surname><given-names>S</given-names></string-name>, <string-name><surname>Lancellotti</surname><given-names>P</given-names></string-name>, <string-name><surname>LeFevre</surname><given-names>M</given-names></string-name>, <string-name><surname>Miller</surname><given-names>F</given-names></string-name>, <string-name><surname>Otto</surname><given-names>CM</given-names></string-name>. <article-title>Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography</article-title>. <source xml:lang="en">J Am Soc Echocardiogr</source>. <year>2017</year>;<volume>30</volume>:<fpage>372</fpage>–<lpage>392</lpage>.<pub-id pub-id-type="pmid">28385280</pub-id></mixed-citation>
              </ref>
              <ref id="jah35745-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="jah35745-cit-0038"><string-name><surname>Concato</surname><given-names>J</given-names></string-name>, <string-name><surname>Peduzzi</surname><given-names>P</given-names></string-name>, <string-name><surname>Holford</surname><given-names>TR</given-names></string-name>, <string-name><surname>Feinstein</surname><given-names>AR</given-names></string-name>. <article-title>Importance of events per independent variable in proportional hazards analysis, I: background, goals, and general strategy</article-title>. <source xml:lang="en">J Clin Epidemiol</source>. <year>1995</year>;<volume>48</volume>:<fpage>1495</fpage>–<lpage>1501</lpage>.<pub-id pub-id-type="pmid">8543963</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
